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ABSTRACT 
Background: Women account for 19% of new HIV diagnoses in the United 
States, with women of color (WOC) comprising 83% of this group. Pre-exposure 
prophylaxis (PrEP) is a safe and effective method of HIV prevention for women. Yet, 
prescribing to WOC remains disproportionately low, leaving a major gap in HIV 
prevention options for this population. The purpose of this study was to examine PrEP 
implementation barriers and facilitators in a high HIV incidence setting in order to 
identify strategies to better provide comprehensive HIV prevention options for WOC. 
Methods: This study used a case study approach with qualitative data collection 
to examine PrEP implementation for WOC as it happened in the “real world” in three 
clinical settings: a community-based clinic, a pediatric emergency department, and a 
Federally Qualified Health Center. Guided by the integrated-Promoting Action on 
Research Implementation in Health Services (i-PARIHS) implementation science 
framework, two rounds of semi-structured interviews were conducted with clinical staff 
and providers. Data analysis was completed according to the five steps of the Framework 
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Method. 
 Results:  By the end of the one-year implementation period, only three WOC had 
been prescribed PrEP out of the targeted 387. Staff cited support of PrEP provision 
among staff and leadership, PrEP alignment with their clinics’ missions, having a 
centralized PrEP coordinator, and relationships with other implementing sites and within 
the local community as implementation facilitators. Despite these supportive factors, staff 
reported time limitations, resistance to PrEP prescribing, discomfort with PrEP 
counseling, and managing different and changing priorities across clinic departments as 
implementation barriers.  
 Conclusion: Though the clinics seemed well-positioned for PrEP 
implementation, significant challenges impeded their success. To successfully provide 
PrEP to women, implementation should include clarifying staff roles and responsibilities, 
engaging staff and providers through ongoing and targeted feedback, and ensuring care is 
focused on women’s needs and experiences. The HIV epidemic can only be fought by 
utilizing all available HIV prevention tools in combination with HIV treatment, delivered 
with consideration of the local context and population. Specific practice 
recommendations identified will support clinics as they provide PrEP to WOC. 
  
  ix 
TABLE OF CONTENTS  
DEDICATION ............................................................................................................... iv 
ACKNOWLEDGMENTS ............................................................................................... v 
ABSTRACT ..................................................................................................................vii 
TABLE OF CONTENTS ............................................................................................... ix 
LIST OF TABLES ...................................................................................................... xiii 
LIST OF FIGURES ....................................................................................................... xv 
LIST OF ABBREVIATIONS ....................................................................................... xvi 
CHAPTER ONE: INTRODUCTION .............................................................................. 1 
1.1 Dissertation overview ................................................................................................ 1 
1.2 Background ............................................................................................................... 2 
1.3 Study context ............................................................................................................. 5 
1.3.1 HIV in the District of Columbia .......................................................................... 5 
1.3.2 PrEP in the District of Columbia ......................................................................... 7 
1.3.3 The PrEP for Women Initiative ........................................................................... 8 
1.4 Problem Statement ..................................................................................................... 9 
1.5 Research purpose, question, aims, and approach ...................................................... 10 
1.6 Rationale and significance ....................................................................................... 12 
CHAPTER TWO: LITERATURE REVIEW ................................................................. 14 
2.1 Chapter overview..................................................................................................... 14 
2.2 PrEP clinical guidelines ........................................................................................... 14 
2.2.1 PrEP clinical considerations for women ............................................................ 15 
  x 
2.2.2 PrEP uptake in the United States ....................................................................... 19 
2.3 PrEP implementation in the United States ................................................................ 22 
2.3.1 PrEP demonstration projects ............................................................................. 23 
2.3.2 Other PrEP care models .................................................................................... 27 
2.4 Review of available PrEP implementation guidance ................................................ 29 
2.5 Women of color and providers’ perspectives on PrEP .............................................. 31 
2.5.1 Women of color’s perspectives on PrEP use...................................................... 32 
2.5.2 Providers’ perspectives on PrEP ........................................................................ 36 
2.5.3 Summary of literature ....................................................................................... 40 
2.6 Discussion ............................................................................................................... 43 
CHAPTER THREE: RESEARCH DESIGN AND METHODS ..................................... 46 
3.1 Chapter overview..................................................................................................... 46 
3.2 Research approach and conceptual framework ......................................................... 46 
3.2.1 Case study approach ......................................................................................... 46 
3.2.2 I-PARIHS conceptual framework ...................................................................... 48 
3.3 Research aims and methods ..................................................................................... 51 
3.3.1 Data collection and analysis .............................................................................. 56 
3.4 Protection of human subjects ................................................................................... 59 
CHAPTER FOUR: CASE STUDIES ............................................................................ 60 
4.1. Chapter overview .................................................................................................... 60 
4.2 Site A case study ..................................................................................................... 60 
4.2.1 Themes related to implementation barriers ........................................................ 61 
  xi 
4.2.2 Themes related to implementation facilitators ................................................... 65 
4.3 Site B case study ...................................................................................................... 69 
4.3.1 Themes related to implementation barriers ........................................................ 70 
4.3.2 Themes related to implementation facilitators ................................................... 74 
4.4 Site C case study ...................................................................................................... 76 
4.4.1 Themes related to implementation barriers ........................................................ 77 
4.4.2 Themes related to implementation facilitators ................................................... 82 
4.5 Chapter summary..................................................................................................... 85 
CHAPTER FIVE: DISCUSSION AND CONCLUSION ............................................... 88 
5.1 Chapter overview..................................................................................................... 88 
5.2 Discussion and practice recommendations ............................................................... 88 
5.3 Recommendations for health policy ......................................................................... 99 
5.4 Recommendations for future research .................................................................... 100 
5.5 Utility of the i-PARIHS framework ....................................................................... 101 
5.6 Study limitations .................................................................................................... 104 
5.7 Conclusion ............................................................................................................ 105 
APPENDICES ............................................................................................................ 108 
Appendix A. Supplemental tables ................................................................................ 108 
Appendix B. Supplemental figures .............................................................................. 113 
Appendix C. Interview guides ..................................................................................... 115 
Appendix D. Washington AIDS Partnership blank quarterly progress report ............... 121 
Appendix E. Case studies’ supplemental tables............................................................ 123 
  xii 
Appendix F. Public health product #1: Patient education tool ...................................... 127 
Appendix G. Public health product #2: PrEP implementation practice recommendations 
reference guide for health clinic staff and providers serving WOC ............................... 129 
Appendix H. Abstract for draft manuscript .................................................................. 131 
BIBLIOGRAPHY ....................................................................................................... 132 
CURRICULUM VITAE .............................................................................................. 153 
  
  xiii 
LIST OF TABLES 
Table 1. Proportions of HIV cases living in DC and newly diagnosed HIV cases by 
race/ethnicity, gender identity, and mode of transmission ..................................... 6 
Table 2. Distribution of number of PrEP users and PrEP need in the United States by 
selected demographic categories, Q4 2017 ......................................................... 22 
Table 3. Review of available PrEP implementation guidance ......................................... 30 
Table 4. The five main stages of case study research for the PrEP for Women Initiative 
implementation study ......................................................................................... 47 
Table 5. I-PARIHS constructs as related to the PrEP for Women Initiative .................... 51 
Table 6. Research aims with related purpose, data collection plan, and data analysis 
method ............................................................................................................... 52 
Table 7. I-PARIHS constructs with corresponding interview questions .......................... 54 
Table 8. Administrative data collected for the PrEP for Women initiative ...................... 55 
Table 9. Implementation barriers and facilitators, organized by the i-PARIHS constructs 
of innovation, recipients, and context ................................................................. 87 
Table 10. Practice recommendations and related strategies for PrEP delivery to WOC 107 
Supplemental Table 1. US Department of Health and Human Services, ART initiation 
expert panel recommendations, updated January 28, 2017 ................................ 108 
Supplemental Table 2. Selected demographics of DC wards, 2011 .............................. 108 
Supplemental Table 3. List of PrEP service locations in Washington, DC  ................... 108 
Supplemental Table 4. US Public Health Service 2017 summary of guidance criteria for 
PrEP use  ......................................................................................................... 109 
  xiv 
Supplemental Table 5. US Public Health Service recommended indications for PrEP use 
by heterosexually active men and women ........................................................ 110 
Supplemental Table 6. US Public Health Service risk behavior assessment for 
heterosexual men and women  ......................................................................... 110 
Supplemental Table 7. Completed and ongoing US PrEP demonstration projects as of 
May 2019 ........................................................................................................ 111 
Supplemental Table 8. PrEP for Women Initiative: Patient/client demographic table, 
provided by the Washington AIDS Partnership ................................................ 122 
Supplemental Table 9. Site A PrEP for Women Initiative overview of main components
 ........................................................................................................................ 123 
Supplemental Table 10. Site A PrEP for Women Initiative timeline ............................. 123 
Supplemental Table 11. Site B PrEP for Women Initiative overview of main components
 ........................................................................................................................ 124 
Supplemental Table 12. Site B PrEP for Women Initiative timeline ............................. 125 
Supplemental Table 13. Site C PrEP for Women Initiative overview of main components
 ........................................................................................................................ 126 
Supplemental Table 14. Site C PrEP for Women Initiative timeline ............................. 126 
 
  
  xv 
LIST OF FIGURES 
Figure 1. New PrEP starts by race/ethnicity and sex, 2012-2015 .................................... 21 
Figure 2. Successful implementation in the i-PARIHS framework ................................. 50 
Supplemental Figure 1. New HIV diagnoses in the US for the most-affected 
subpopulations ................................................................................................. 113 
Supplemental Figure 2. New TDF-FTC for PrEP starts by race/ethnicity and age, 2012-
2015................................................................................................................. 113 
Supplemental Figure 3. Number of newly diagnosed HIV cases and living HIV cases by 
year District of Columbia, 2012-2016 .............................................................. 114 
 
  
  xvi 
LIST OF ABBREVIATIONS 
AAFP  American Association of Family Physicians 
ACOG  American College of Obstetricians and Gynecologists 
AIDS  Acquired Immunodeficiency Syndrome 
ART  Anti-retroviral Treatment 
CDC  Centers for Disease Control and Prevention 
CPT  Current Procedural Terminology 
DBS  Dried Blood Spot 
DC  District of Columbia 
DOH  Department of Health 
ED  Emergency Department 
EMR  Electronic Medical Record 
FDA  Food and Drug Administration 
FPL  Federal Poverty Line 
FQHC  Federally Qualified Health Center 
FTC  Emtricitabine  
HHS  Health and Human Services 
HIV  Human Immunodeficiency Virus 
HPTN  HIV Prevention Trials Network 
ICD  International Classification of Diseases  
i-PARIHS Integrated-Promoting Action on Research Implementation in Health 
Services  
  xvii 
IDU  Intravenous Drug User 
IPV  Intimate Partner Violence 
IRB  Institutional Review Board 
LGBT  Lesbian, Gay, Bisexual, and Transgender 
MSM  Men Who Have Sex with Men 
OI  Opportunistic Infection 
PCP  Primary Care Physician 
POCT  Point-of-care Testing 
PrEP  Pre-exposure Prophylaxis 
PWI  PrEP for Women Initiative 
RA  Research Assistant 
RFA  Request for Application 
RNI  Risk Not Identified 
STI  Sexually Transmitted Infection 
TDF  Tenofovir Disoproxil Fumarate 
US  United States 
USPHS United States Public Health Service 
USPSTF United States Preventive Services Task Force  
WAP  Washington AIDS Partnership 
WHO  World Health Organization 
WOC  Women of Color 
YWOC Young Women of Color   
  1 
CHAPTER ONE: INTRODUCTION 
1.1 Dissertation overview 
The purpose of this study was to examine the implementation of the Pre-exposure 
prophylaxis (PrEP) for Women Initiative. The PrEP for Women Initiative (PWI), 
implemented in three health clinics in Washington, District of Columbia (DC), aimed to 
increase PrEP uptake among women of color (WOC) by building the capacity of medical 
providers and clinics to offer PrEP as an effective HIV prevention strategy. I used 
qualitative methods, along with the collection of administrative data, to examine 
implementation barriers and facilitators, and identify strategies to support and improve 
PrEP for women. 
Chapter 1 includes background information on HIV, PrEP, and the PWI; 
describes the study’s context and significance for public health; and provides an overview 
of the research question and aims. Chapter 2 reviews literature on PrEP demonstration 
projects in the US, PrEP service delivery models, existing PrEP guidance, and barriers 
and facilitators to PrEP uptake and implementation identified in previous research from 
the perspectives of WOC and providers, respectively. Chapter 3 provides a detailed 
description of the research approach, conceptual framework, and study methods. 
Chapters 4 presents three case studies examining each clinic’s implementation of the 
PWI. Chapter 5 concludes with a discussion of findings, recommendations for public 
health practice, and limitations. Products developed from this dissertation are included in 
the appendices: 1) a patient education tool that provides an easy-to-digest overview of 
women’s options for the prevention of sexually transmitted infections (STIs), HIV, and 
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pregnancy; 2) PrEP implementation practice recommendations reference guide for health 
clinic staff and providers serving WOC; and 3) a draft of a manuscript to be submitted to  
a peer-reviewed journal examining PrEP implementation barriers and facilitators from the 
perspectives of clinic staff and providers. 
1.2 Background 
HIV progressively weakens a person’s immune system by destroying the CD4 T-
lymphocytes (CD4 cells), which coordinate the immune system’s response to foreign 
pathogens (1). Blood, vaginal or seminal fluid, and breast milk containing HIV can be the 
source of mucous membrane or blood-borne transmission of HIV (2). If left untreated, 
HIV leads to AIDS, which is diagnosed when the CD4 cell count is below 200 cells per 
cubic millimeter of blood (cells/mm3) or upon manifestation of  an opportunistic 
infections (OI) designated as an AIDS-defining illnesses (2). Currently, there is no cure 
for HIV. However, highly active antiretroviral therapies (ART) can reduce viral load, 
restore immune function, and improve quality of life (3). The US Department of Health 
and Human Services (HHS) has developed recommendations for ART initiation and 
management for HIV-infected patients, updated annually, based on the review of its 
expert panel.1 
As of  2016, an estimated 1.1 million people aged 13 and older in the US were 
living with HIV (4). Over 38,000 people were newly diagnosed with HIV in 2017, with 
women accounting for 19% of new HIV diagnoses (5). Heterosexual contact with a man 
living with HIV was the most common method of HIV acquisition among women in the 
                                               
1 See Appendix A, Supplemental Table 1 for US HHS ART guidelines 
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US (5).2 Biological, interpersonal, economic, and structural factors make women more 
vulnerable to HIV than men. Biologically, women are more susceptible to HIV infection 
as the vagina provides a large surface area through which HIV can enter, and the cervix 
contains numerous CD4 cells (6). Additionally, having a STI increases the risk of HIV 
transmission (7). At the interpersonal level, intimate partner violence (IPV) and power 
differentials (i.e., women have less power in a heterosexual relationship that affects the 
use of condoms and other HIV prevention methods) increases women’s vulnerability to 
HIV (8,9). Economic factors (e.g., poverty) and structural factors (e.g., HIV-related 
stigma, limited access to health care) also increase the risk of HIV acquisition for women 
(8,9).  
African American/Black women and Hispanic/Latina women make up 66% and 
17% of new HIV infections among women, respectively, in the US (5). African 
American/Black communities have a higher prevalence of STIs and thus elevated risk of 
HIV acquisition (10). Substance abuse and IPV have also been associated with increased 
risk of HIV for WOC (11–15). WOC’s access to HIV prevention services is limited by 
poverty, unemployment, stigma, a lack of culturally-appropriate care, mistrust of medical 
institutions, and fear of discrimination by the health care system  (11,16,17). African 
American/Black women have also described having limited autonomy to negotiate sexual 
health decisions, including safer sex practices (18,19).  
PrEP is the use of antiretroviral medications for the prevention of HIV acquisition 
                                               
2 See Appendix B, Supplemental Figure 1 for count of new HIV diagnoses in the US for the most-
affected subpopulations in 2017 by race/ethnicity and mode of transmission. 
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in uninfected individuals. In 2012, the US Food and Drug Administration (FDA) 
approved Truvada®, a daily oral tablet that combines tenofovir and emtricitabine (TDF-
FTC), as PrEP (20).3,4 The 2017 US Public Health Service (USPHS) clinical guidelines 
recommend PrEP as a prevention option for adult women who are heterosexually active 
or inject drugs, and are at “substantial risk of HIV acquisition” (21). In 2019, the US 
Preventive Services Task Force (USPSTF) gave PrEP a grade A rating, meaning that they 
determined PrEP to have substantial benefit of decreasing the risk of HIV infection in 
persons at high risk of HIV infection (22). USPSTF recommends offering PrEP to 
heterosexually active women with one of the following risk factors: a serodiscordant 
sexual partner; inconsistent condom use with a partner with unknown HIV status or who 
is at high risk; or a STI with syphilis or gonorrhea in the past six months (22).  
The US Centers for Disease Control and Prevention (CDC) estimate that 1.1 
million US adults have indications for PrEP, including 176,670 heterosexual females 
(23). A recent study identified PrEP users as 4.6%  (n = 3,229) female compared to 
95.4% (n = 70,395) male as of the end of 2017; according to the CDC estimate, women 
should compose at least 16% of PrEP users (23,24). Other studies using retail pharmacy 
data and a national prescription database show that PrEP prescribing is disproportionately 
lower among women (particularly among African American/Black women), persons aged 
24 and younger, persons who lived in the South (including DC), and states with the 
                                               
3 Pre-exposure prophylaxis for HIV infection also comes in other forms such as insertables, patches, 
and gels. Only the Truvada® tablet has been approved as PrEP for HIV infection in the US. 
Throughout this dissertation, PrEP will refer to the Truvada® tablet.  
4 In May 2018, the FDA updated its PrEP indication to include adolescents who weigh at least 77 
pounds (204).   
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highest proportion of African American/Black residents (24,25). Section 2.2.2 further 
describes PrEP uptake in the US, and racial and gender disparities in PrEP use.   
1.3 Study context 
 
In 2017, Washington, DC had approximately 700,000 residents within its eight 
wards (26). DC residents were 48% African American/Black, 45% White, and 4% Asian, 
with the remainder identifying as another race. Eleven percent of residents identified as 
of Hispanic/Latino ethnicity, and approximately 14% of residents were immigrants, 
primarily from African, Latino, or Caribbean countries (26,27). About 19% of DC 
residents lived below the federal poverty line (FPL) (26). Wards 7 and 8 are 
predominantly African American/Black (95% and 94%, respectively) and have the lowest 
median income of all wards ($36,828 and $30,653, respectively) (26).5 As of February 
2017, there were five Federally Qualified Health Centers (FQHC)6 and one full service 
hospital7 serving Wards 7 and 8 (28,29).  
1.3.1 HIV in the District of Columbia 
HIV prevalence in DC remains the highest in the US at 1.9%, although newly  
diagnosed HIV cases in DC decreased 52% between 2011 and 2016 (30). In 2016, nearly 
94% of DC women living with HIV were African American/Black (30). African 
American/Black women who report heterosexual HIV transmission represented the 
second largest proportion of people living with HIV and the second largest proportion of 
                                               
5 See Appendix A, Supplemental Table 2 for selected DC demographics by ward. 
6 The five FQHC are: Unity Health Care, Inc.; Community of Hope; Elaine Ellis Center for Health; 
Family and Medical Counseling; and Whitman Walker Max Robinson Clinic. 
7 The hospital is United Medical Center, which is scheduled to close by 2023. 
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newly diagnosed HIV cases by race/ethnicity and mode of transmission, Table 1 (31). 
Though HIV prevalence among immigrants in DC is not known, DC’s Integrated 
HIV/AIDS Prevention and Care Plan specifies immigrants and African American/Black 
women as priority populations for HIV prevention (32). Wards 5, 7, and 8 had the 
greatest number of new and previously diagnosed HIV cases (30).8  
Table 1. Proportions of HIV cases living in DC and newly diagnosed HIV cases 
by race/ethnicity, gender identity, and mode of transmission (31) 
  Proportion of 
HIV cases, 2017 
Proportion of newly 
diagnosed HIV cases, 
2013-2017 
Black MSM and MSM/IDU 27% 26% 
Black heterosexual men 9% 9% 
Black men other/RNI 7% 12% 
Black men IDU 5% 1% 
Black heterosexual women 16% 14% 
Black women other/RNI 3% 6% 
Black women IDU 4% 1% 
White MSM and MSM/IDU 14% 12% 
White men other 2% 2% 
Latino MSM and MSM/IDU 5% 7% 
Latino men other 1% 2% 
Other* 3% 4% 
Transgender persons 1.40% 3% 
Latina women 1% 0.40% 
White women 0.40% 1% 
MSM=men who have sex with men; IDU=injection drug user; RNI=risk not identified; 
Other=perinatal transmission, hemophilia, blood transfusion, and occupational exposure; non-
MSM=all modes of transmission excluding MSM and MSM/IDU; Latino men 
other=heterosexual, IDU, RNI, and other modes of transmission; Black women other=RNI and 
other modes of transmission; Black men other=RNI and other modes of transmission; Latina 
women=all modes of transmission; White women=all modes of transmission; Transgender 
person=includes both transgender men and transgender women. 
*Other=all persons of other race with all modes of transmission. 
 
                                               
8 See Appendix B, Supplemental Figure 3 for trends of newly diagnosed HIV cases and living HIV 
cases by year for DC, 2012-2016. 
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1.3.2 PrEP in the District of Columbia 
In 2016, DC’s mayor released the 90/90/90/50: Ending the HIV Epidemic in the 
District of Columbia by 2020 report (33). The mayor’s plan aims to achieve the following 
four goals by 2020: 1) 90% of DC residents with HIV will know their status; 2) 90% of 
DC residents diagnosed with HIV will be in treatment; 3) 90% of DC residents in 
treatment will achieve viral load suppression; and 4) DC will see a 50% decrease in the 
number of new HIV diagnoses (33).  
The plan calls for increased implementation of prevention interventions, 
particularly PrEP, for groups at highest risk of infection including African 
American/Black heterosexual women (33). The plan states the need to “identify those 
who test negative [for HIV] but are at elevated risk, and engage counseling for prevention 
strategies, including counseling for PrEP” (33). The plan also calls for more PrEP 
prescribers by increasing medical providers’ knowledge and capacity to introduce and 
counsel patients on PrEP (33). To reach a 50% decrease in the number of new HIV 
diagnoses, the plan estimates that 8,000 DC residents need to be on PrEP consistently 
(33). The CDC estimates that 13,820 adults in DC are indicated for PrEP, including 4,210 
heterosexual adults (23).9 As of 2016, the DC Department of Health (DOH) estimated 
that about 2,000 DC residents have ever been prescribed PrEP, with 1,000 of those 
                                               
9 The CDC estimated number of DC heterosexual adults with indications for PrEP is not stratified by 
gender.  
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prescriptions written in 2016 (30,33).10,11 As of 2016, fourteen sites offer PrEP services in 
DC.12 Three of these sites focus on serving the lesbian, gay, bisexual, and transgender 
(LGBT) community while the remainder serve the general public. Only four sites are 
located in the higher incidence wards 5 and 8, and none were located in ward 7 (34).  
1.3.3 The PrEP for Women Initiative 
The PrEP for Women Initiative (PWI) began as a one-year demonstration project 
ordered by the 90/90/90/50 plan. The DC DOH and the Washington AIDS Partnership 
(WAP), a grant-making organization that supports local HIV prevention and care efforts, 
formed a public-private partnership to develop the PWI. The PWI aimed to improve 
knowledge about PrEP use for high-risk WOC in Washington, DC. To reach this aim, the 
PWI established four goals: 1) leverage HIV and women’s health providers to adopt and 
offer PrEP as an effective strategy to reduce HIV infection; 2) educate women at high 
risk for HIV to normalize and increase interest in PrEP; 3) change and expand the 
conversation about PrEP and women from “protecting her from him” to “taking care of 
yourself”; and 4) increase the knowledge and number of health providers prescribing 
PrEP for women (35).  
The DOH-WAP collaborative released a Request for Applications (RFA) to 
address these gaps in services for women. The RFA was widely distributed among DC 
                                               
10 This estimate is based on reports from community-based providers offering PrEP and does not 
include private practice providers. DC DOH notes three challenges with collecting PrEP data: 1) PrEP 
does not have a diagnostic code, under the International Classification of Diseases (ICD) system; 2) 
there is no Current Procedural Terminology (CPT) code for PrEP; and 3) PrEP is not a reportable 
health condition (33). 
11 The DC DOH estimate is not broken down by demographics (e.g., race, gender) or mode of 
transmission. 
12 See Appendix A, Supplemental Table 3 for complete list of sites providing PrEP in DC. 
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organizations that serve WOC. Three DC health clinics were selected to implement the 
PWI, based on their expertise in providing health services for WOC, including sexual 
and/or reproductive health services. Each of the clinics developed their own 
implementation plan and established their own goals to meet the overarching initiative 
goals. These clinics are described below: 
• Site A, a non-profit community-based clinic, provides reproductive health care, 
cancer screenings, and women’s health care in the DC region, reaching over 
15,000 clients in 2016. Under the PWI, Site A focused on providing PrEP services 
to WOC aged 19-55 through their educational and clinical programs.  
• Site B, the largest pediatric health system in DC, has operated a pediatric 
Emergency Department (ED) HIV point-of-care testing (POCT) program since 
2009. Under the PWI, Site B focused on increasing the uptake of PrEP among 
young women of color (YWOC) aged 13-24 who screen positive for a STI 
through the POCT program.  
• Site C is a Federally Qualified Health Center, originally founded as a community-
based non-profit to address the needs of recently arrived Central American 
immigrants. Under the PWI, Site C employed a 2-step PrEP process in which 
patients who expressed interest or were identified as eligible by providers were 
referred to a PrEP nurse coordinator for a separate PrEP initiation visit.  
1.4 Problem Statement 
Daily oral PrEP is safe and effective method for HIV prevention. Yet, PrEP 
prescribing is disproportionately low for women. As safety and efficacy of PrEP for 
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women have been demonstrated, there is now a growing interest in how best to 
implement PrEP and reach individuals at substantial risk of HIV. However, few 
demonstration projects have focused on PrEP provision for WOC. In order to understand 
how to best provide PrEP to WOC, this dissertation examines the implementation of the 
PrEP for Women Initiative in the above mentioned three clinics in Washington, DC.  
1.5 Research purpose, question, aims, and approach 
In its 2014 framework for PrEP demonstration projects, the World Health 
Organization (WHO) stated that to successfully implement PrEP, qualitative research on 
barriers to PrEP prescribing from the perspective of providers, and methods to address 
these barriers, is needed (36). A 2015 special implementation-focused issue of the 
Journal of the International AIDS Society stated that “case studies in PrEP 
implementation in diverse environments” are needed to inform the HIV prevention field 
(77, p. 2). As the focus of the PWI was to leverage providers to prescribe PrEP to WOC, 
it is important to understand the experiences of the three organizations charged with the 
implementation of the PWI. To that end, the purpose of this dissertation was to examine 
the implementation facilitators and barriers from the perspectives of clinic staff and 
providers in three unique settings: a nonprofit community-based clinic, a hospital-based 
ED, and a FQHC.  
This dissertation seeks to answer the following public health question: What 
lessons can be learned by examining a novel PrEP for women initiative in order to 
improve the current program, inform future programs, and better provide a fuller range of 
HIV prevention options for WOC? The answer to this question was explored by 
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addressing two specific aims, below (further detailed in section 3.3):  
• Aim 1. Examine the implementation of the PrEP for Women Initiative. 
o Sub-aim 1.1. Describe each site’s progress towards initiative goals.  
o Sub-aim 1.2. Examine PrEP implementation barriers and facilitators. 
• Aim 2. Develop practice recommendations to support and improve PrEP 
implementation for WOC. 
This dissertation used a case study approach, with each setting presented as a case 
for examination. This approach allows for examination of PrEP implementation in the 
“real world” outside of experimental clinical trials (38). A case study provides a holistic 
understanding of the multiple factors impacting implementation, and uses theory to drive 
data collection and interpretation (39). Case studies have been used to explore 
implementation of HIV programs and policies, including test and treat initiatives, rapid 
HIV testing strategies, and multi-level HIV prevention interventions (40–42). Rather than 
an experimental design which attempts to test a specific hypothesis by controlling or 
manipulating variables of interest, a case study approach allows for information to be 
captured in the natural environment and provides insight into implementation gaps 
(38,43). 
The integrated-Promoting Action on Research Implementation in Health Services 
(i-PARIHS) framework informed the design and methods of this study (44). The i-
PARIHS framework aims to explain the many intertwined factors that influence 
evidence-based health practice implementation (44). The framework examines four core 
constructs: 1) facilitation: how does implementation happen, that is, the process of 
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navigating individuals and teams through change and challenges; 2) innovation: what is 
being implemented (PrEP); 3) recipients: who is involved in the implementation (clinic 
staff and providers); and 4) context: where does the implementation occur, including both 
inner (within the organization) and outer (wider health system or health policy) contexts 
(44). Successful implementation is contingent on the facilitation process activating 
implementation through assessing and responding to the innovation and recipients within 
the specific context (44,45). 
Study methods are detailed in Chapter 3. I used routine administrative data to 
describe each site’s progress towards the initiative goals. Each site collected these data 
and reported the data to WAP as a requirement of the grant. I conducted and analyzed 
semi-structured, one-on-one interviews with staff and providers at each site to examine 
implementation barriers and facilitators. I reviewed site documents, including workplans, 
training curricula, and outreach materials to gain an understanding of sites’ 
implementation activities. I conducted a literature review (Chapter 2) to inform, in 
combination with the interview findings, the development of practice recommendations 
for PrEP implementation for WOC.  
1.6 Rationale and significance 
Though the efficacy and safety of PrEP has been established, there are still 
significant gaps in translating the clinical knowledge into effective public health practice. 
Current and past US demonstration projects examining how to implement PrEP in the 
real world have focused on key populations affected by HIV including men who have sex 
with men (MSM), and to a lesser extent, transgender persons and people who engage in 
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sex work. However, in high HIV incidence areas, heterosexual women, particularly 
WOC, are at substantial risk of HIV infection and should therefore be engaged in PrEP 
programs.  
The lack of PrEP prescribing for WOC and uncertainty about best practices for 
implementation of these programs leave a major gap in HIV prevention options for this 
population who make up more than half of the new HIV diagnoses among women (5). 
The PWI in Washington, DC was the first city-wide initiative in the US aimed 
specifically at increasing the uptake of PrEP among WOC. This initiative created the 
opportunity to take a critical, in-depth look at PrEP implementation across three unique 
services settings in a high HIV incidence area. By understanding the implementation 
process and developing practice recommendations for PrEP implementation for WOC, 
results from this dissertation will assist in the development of similar initiatives across 
the US, and therefore advance HIV prevention efforts for WOC. 
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CHAPTER TWO: LITERATURE REVIEW 
2.1 Chapter overview 
 The purpose of this chapter is to review the available literature on PrEP for 
women. To that end, I discuss PrEP clinical guidelines and considerations for women. I 
describe PrEP implementation in the US including formal demonstration projects and 
other care models. Then, I review published PrEP implementation guidance and literature 
examining PrEP uptake and implementation from the perspectives of WOC and 
providers, respectively. Finally, I end with a discussion of lessons learned and key gaps 
in the literature on providing PrEP for WOC. I used this literature review, combined with 
findings from this study, to develop practice recommendations for PrEP implementation 
for WOC (Chapter 5). 
2.2 PrEP clinical guidelines 
 
The 2017 US Public Health Service’s clinical guidelines (also referred to as CDC 
guidelines) recommend PrEP as a prevention option for adult women who are 
heterosexually active or inject drugs and are at “substantial risk of HIV acquisition” 
(46).13 In addition to assessing risk and clinical eligibility, the guidelines recommend that 
providers offer education on PrEP and create an adherence plan with their patients prior 
to initiation (46). The American College of Obstetricians and Gynecologists (ACOG) 
recommends that women be considered for PrEP if they have a male HIV-positive sexual 
partner (47). Additionally, per ACOG’s recommendation, women should be considered 
                                               
13 Complete US Public Health Service’s summary guidance for PrEP use, recommended indications 
for PrEP use, and risk behavior assessment for heterosexual men and women can be found in 
Appendix A, Supplemental Tables 4, 5, and 6 respectively. 
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for PrEP if they live in a high HIV prevalence area,14 have a partner with unknown HIV-
status, or report any of the following: inconsistent or no condom use, STI diagnosis, 
engagement in sex work, use of intravenous drugs, alcohol dependency, or incarceration 
(47). In 2019, the US Preventive Services Task Force (USPSTF) gave PrEP a grade A 
rating, determining with high certainty that PrEP has substantial benefit of decreasing the 
risk of HIV infection in persons at high risk of HIV infection (22). USPSTF recommends 
PrEP for heterosexually active women with any of the following risk factors: a 
serodiscordant sexual partner; inconsistent condom use with a partner with unknown HIV 
status or who is at high risk; or a STI with syphilis or gonorrhea in the past six months 
(22). The USPSTF also cites that risk behaviors in a high HIV prevalence setting have a 
higher risk of HIV acquisition than the same risk behaviors in a low HIV prevalence 
setting (22). 
2.2.1 PrEP clinical considerations for women 
 
2.2.1.1 PrEP adherence considerations for women 
Findings from international PrEP efficacy trials involving women have been 
mixed. The Partners PrEP trial, conducted from 2008-2010 in Kenya and Uganda, 
enrolled heterosexual serodiscordant couples. HIV-negative participants (n = 4,758) were 
assigned to one of three study groups (once-daily tenofovir disoproxil fumarate [TDF]; 
combination tenofovir emtricitabine [TDF-FTC]; or placebo) and followed monthly for 
36 months (48). For women, TDF and TDF-FTC significantly decreased HIV incidence, 
with a 71% reduction with TDF and a 66% reduction with TDF-FTC relative to placebo, 
                                               
14 ACOG does not define high prevalence area.  
  16 
respectively (48). The TDF2 trial conducted in Botswana confirmed the efficacy of TDF-
FTC in reducing the risk of HIV infection (49). Heterosexual men and women (n = 
1,219) were enrolled into two groups, TDF-FTC or placebo (49). The trial found a 62% 
reduction in HIV incidence compared to placebo (49).15  
However, results from two large PrEP clinical trials conducted in exclusively 
female samples, the PrEP Trial for HIV Prevention among African Women (FEM-PrEP) 
and the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trials, differed 
from results seen in the Partners PrEP and TDF2 studies (50,51). FEM-PrEP assigned 
women (n = 2,120) from three sub-Saharan African countries to receive either TDF-FTC 
or a placebo (50). FEM-PrEP began in 2008, but was stopped early in 2011 due to the 
lack of demonstrated treatment efficacy in reducing the risk of HIV infection (50). The 
VOICE study echoed the FEM-PrEP findings. VOICE randomized women (n = 5,029) 
from three sub-Saharan African countries into four study arms: 1) TDF; 2) TDF-FTC; 3) 
1% tenofovir vaginal gel; or 4) placebo control arm (51). Groups one and three were 
stopped after interim analyses determined futility; outcome analyses did not find any 
method that significantly reduced the risk of HIV infection compared to a placebo (51). 
Importantly, both VOICE and FEM-PrEP study populations had low PrEP 
adherence (50,51). VOICE-C, a qualitative follow-on study among VOICE participants, 
identified a number of potential explanations for low PrEP adherence in the VOICE trial, 
including the challenges posed by a daily regimen, lack of social support, and concerns 
about side effects (52). Though PrEP efficacy trials with women have shown mixed 
                                               
15 TDF2 trial results were not reported separately by sex. 
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results, a 2016 meta-analysis of five major randomized efficacy trials16 including women 
showed that oral PrEP can be efficacious in reducing risk of HIV infection for women 
when adherence to daily PrEP is at least 75% (53).  
In order to reach high efficacy, women may need to achieve higher levels of 
adherence than men. Pharmacokinetic studies have found that among participants who 
reported daily dose adherence in the last three days, a single dose of TDF showed 
significantly lower concentrations of TDF in vaginal and cervical tissue compared to 
rectal tissue (54,55). Drug detectability was also lower in women compared to men, at 
92% v. 98%, respectively (54,55). The HIV Prevention Trials Network (HPTN) 067 trial, 
also known as the ADAPT Cape Town Trial, examined different dosing strategies in an 
exclusively female sample. ADAPT randomized women into three study arms: daily 
dosing; twice weekly dosing with post-intercourse boost; or event-driven dosing (i.e., 
taking PrEP both before and after sexual intercourse but not daily). This trial found that 
women who followed daily dosing had better adherence, higher drug levels, and better 
coverage of sex acts than woman in the other arms (56). The habit of daily dosing may 
encourage adherence as well as provide coverage for accidental missed doses (56). 
Coupled with the findings from VOICE-C, these studies demonstrate the importance of 
adherence to daily PrEP among women.  
                                               
16 These trials were: Partners PrEP; TDF2-Botswana; FEM-PrEP; VOICE, and Bangkok-TDF (48–
51,205). Bangkok-TDF trial enrolled men and women who injected drugs.  
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2.2.1.2 Peri-conception, pregnancy, and breastfeeding 
Women are willing to use PrEP in order to meet their conception goals (57). In a 
recent qualitative study of serodiscordant couples, participants described PrEP use during 
conception as a preferred, more “natural” method for conception than technology-assisted 
methods such as in vitro fertilization (IVF) or sperm-washing (58). The 2017 USPHS 
guidelines recommend PrEP as a method to decrease the risk of transmission for HIV-
negative women who wish to conceive with a HIV-positive male partner with unknown 
or detectable viral load (59,60). However, it is unknown if PrEP provides any added 
benefit to the woman when her HIV-positive partner has a suppressed viral load while on 
ART (59).17  
In addition to reducing the risk of HIV transmission during pregnancy, studies 
show that PrEP has no adverse effects on pregnancy and infant outcomes. A 2016 
systematic review of TDF in pregnant women found no evidence of negative pregnancy 
or infant outcomes (including increased risk of pregnancy loss, stillbirth, preterm birth, 
small for gestational age, and infant mortality) compared to similar women receiving 
placebo or non-TDF ART (61). A separate 2016 review of clinical trial safety data 
echoed these findings, but also noted that no conclusion could be made about the safety 
of PrEP for infants with in utero exposure to PrEP throughout pregnancy and 
breastfeeding due to the lack of data (62). That same year, the USPHS expert panel stated 
that for HIV-uninfected women in serodiscordant relationships, PrEP may offer 
                                               
17 There is effectively no risk of HIV transmission from a sexual partner with an undetectable viral 
load (defined as less than 200 copies of HIV per milliliter of blood) (206). 
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protection against HIV for a mother and fetus/child during pregnancy and breastfeeding 
(59). However, the long-term safety of PrEP use by HIV-uninfected women during 
pregnancy or breastfeeding is not yet determined (59). The 2019 USPSTF 
recommendation statement calls for more research on the safety and effectiveness of 
PrEP during pregnancy and breastfeeding (22).18  
2.2.2 PrEP uptake in the United States 
In 2015, the CDC estimated 1.2 million adults, including 468,000 heterosexual 
women, had substantial risk for HIV acquisition and should be offered PrEP according to 
the 2014 USPHS guidelines (63). In 2018, in order to calculate the number of adults with 
indications for PrEP use by transmission risk group and race/ethnicity, the CDC used an 
updated method with state-level HIV surveillance data on the number of new HIV 
diagnoses and publicly available nationally representative data (23). Though the total 
adults with indications for PrEP remained similar to the 2015 estimate at 1.1 million 
adults, the number of heterosexual females estimated to be clinically eligible for PrEP 
declined to 176,670 heterosexual females in the 2018 estimate (23). 
However, a recent study notes that the 2017 update to the 2014 USPHS guidelines 
includes two versions of guidelines: 1) summary of guidance criteria, and 2) 
recommended indications for use criteria (64).19 While the summary of guidance criteria 
                                               
18 For mothers living with HIV that have an undetectable viral load, the risk of transmitting HIV to the 
baby can be 1% or less if the mother takes ART as prescribed throughout pregnancy, labor, and 
delivery and gives ART to her baby for 4-6 weeks after birth. For breastfeeding, the current CDC 
recommendation is that mothers living with HIV should not breastfeed their infants, even if they have 
an undetectable viral load (206). 
19 See Appendix A, Supplemental Tables 4 and 5 for complete summary of guidance criteria and 
recommended indications for use criteria. 
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require that women only report their own behaviors (e.g., history of inconsistent or no 
condom use), the recommended indications require that women be aware of their sexual 
partners’ risk behaviors (e.g., infrequent use of condoms during sex with partner of 
unknown HIV status who are known to be at substantial risk of HIV infection) (64). 
When applied to their study sample (n = 679 women), researchers found significant 
differences in PrEP eligibility based on the summary of guidance criteria compared to the 
recommended indications for use criteria (64). Further, some participants who reported 
that they were interested in learning more about PrEP or motivated to take PrEP were not 
identified as eligible based on either set of criteria (64). Therefore, the CDC estimate may 
be underestimating the number of women eligible for PrEP (64). 
Retail pharmacy data show that 10,193 women initiated PrEP from 2012 to 2015 
(25). The proportion of PrEP initiators who were female declined from 48.5% (n = 2,615) 
in 2012 to 11.4% (n = 2,491) in 2015 (25). In the same time period, 38,955 men initiated 
PrEP, with the proportion of PrEP initiators who were male increasing from 51.5% (n = 
2,778) to 88.6% (n = 19,344) in 2015 (25). A more recent study identified PrEP users as 
4.6% (n = 3,229) female compared to 95.4% (n = 70,395) male as of the end of 2017 
(24). The CDC estimates that 16% of eligible PrEP users should be female (23).  
From 2012-2015, when examined by race, PrEP users were 74% White, 10% 
African American/Black, and 12% Hispanic, with the remainder identified as other or 
multiracial (25). Among both women and men, African Americans/Black individuals and 
Hispanic individuals were significantly less likely than White individuals to initiate PrEP 
(25). African American/Black women were over four times less likely to have initiated 
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PrEP compared to White women between 2012-2015 (25); Figure 1.20 The ratio of PrEP 
prescriptions per new HIV diagnosis (“PrEP-to-need”) was lowest among women, 
persons aged 24 and younger, persons who lived in the South, and states with the highest 
proportion of African American/Black residents (24); Table 2. These studies show that 
though approximately 176,000 women are indicated for PrEP according to the CDC (and 
that this number may be underestimated), PrEP prescribing to women – particularly 
WOC – is disproportionately low.   
Figure 1. New PrEP starts by race/ethnicity and sex, 2012-2015 (25) 
 
*AA=African American 
These data represent 43.7% (n=21,463) of unique individuals who have started FTC/TDF for PrEP from 
2012 through 3rd quarter 2015. Data were collected from national, electronic, patient-level data from US 
retail pharmacies. 
 
  
                                               
20 See Appendix B, Supplemental Figure 2 for new TDF-FTC for PrEP starts by race/ethnicity and 
age, 2012-2015. 
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Table 2. Distribution of number of PrEP users and PrEP need in the United States by 
selected demographic categories, Q4 2017 (24) 
Demographic group 
PrEP users 
N (%) 
PrEP-to-need 
ratio* 
Age 70,432 - 
Less than 24 years 7,990 (11.3) 0.9 
25-35 years 27,556 (39.1) 2.0 
35-44 years 16,991 (24.1) 2.2 
45-54 years 12,121 (17.2) 2 
55 years and older 5,774 (8.2) 1.5 
Gender 70,395 - 
Female 3,229 (4.6) 0.4 
Male 67,166 (95.4) 2.1 
Region 70,365 - 
Midwest 11,963 (17.0) 2.4 
Northeast 20,881 (29.7) 3.3 
South 21,430 (30.5) 1.0 
West 16,091 (22.9) 2.1 
African American concentration (by state) 70,395 - 
Less than 3.3% African American 2,553 (3.6) 3.0 
3.3% - <7.6% African American 19,794 (28.1) 2.0 
7.6% - <15.6% African American 20,179 (28.7) 1.6 
15.6% or more African American 27,869 (39.6) 1.5 
*PrEP-to-need ratio calculated as the number of PrEP users divided by the number of individuals 
newly diagnosed with HIV 
 
2.3 PrEP implementation in the United States 
The US National HIV/AIDS Strategy recognizes that full access to 
comprehensive PrEP services is necessary to achieve its goal of reducing new HIV 
infections by at least 25% (65). A 2015 special implementation-focused edition of the 
Journal of International AIDS Society described PrEP implementation in the US as “a 
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work in progress” (66). PrEP has been implemented across a variety of settings including 
health centers specializing in care for the LGBT population; primary care practices; and 
STI clinics (67–70). Demonstration projects have examined PrEP in the real world, but 
these projects have focused on outcomes rather than the implementation process, and 
none have focused on PrEP for WOC (67–70). I conducted a review of PrEP 
demonstration projects (section 2.3.1) and other PrEP care models (2.3.2) in order to 
identify lessons for implementation.  
2.3.1 PrEP demonstration projects 
Demonstration projects are the step between efficacy trials and full scale 
implementation (36). As of September 2019, four completed PrEP demonstration projects 
in the US have published results: 1) the Demonstration Project; 2) HPTN 073; 3) PATH-
PrEP; and 4) Project PrEPare. Each are described briefly below.21 Though none of these 
projects focused on cisgender WOC, they provide insight into PrEP implementation.  
The first PrEP demonstration project in the US, known as the “Demo” Project, 
was conducted in two municipal STI clinics in San Francisco and Miami, and a 
community health center in Washington, DC from 2012 to 2015 (67). The Demo Project 
aimed to assess the uptake, acceptability, safety, and feasibility of PrEP in a real world 
setting for men who have sex with men (MSM) and transgender women (67). Participants 
(n = 557) received HIV/STI testing, clinical monitoring, PrEP prescribing, and client-
centered risk reduction and adherence counseling by a counselor or clinician at five 
                                               
21 See Appendix A, Supplemental Table 7 for a list of completed and ongoing demonstration projects 
as of May 2019. 
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follow-up visits over 48 weeks (67). Using dried blood spots (DBS), the Demo Project 
found protective concentrations of PrEP in an estimated 86%, 85%, 82%, 85%, and 80% 
of participants across the five study visits (67). African American/Black participants were 
significantly less likely to have protective levels of PrEP (67).22 There was significant 
demand for PrEP, with waitlists in both San Francisco and DC (71). This project 
demonstrated that PrEP prescribing, along with adherence and risk reduction counseling, 
can effectively be implemented for MSM and transgender women in similar clinical 
settings. Additionally, findings suggest that participants of color may require stronger or 
different adherence support than White participants. 
HPTN 073, conducted from 2013 to 2015, assessed initiation, acceptability, 
safety, and feasibility of PrEP for African American/Black MSM in three cities (68). 
Participants (n = 266) were recruited from one community health center and two hospital-
based clinics, prescribed PrEP, and followed for five visits across one year (68). 
Participants received client-centered care coordination known as “C4”: a culturally 
tailored, theory-based counseling method designed to support PrEP use, provide social 
services referrals, and address psychosocial needs (68). Nearly 80% of participants 
accepted PrEP, and 68% of participants remained on PrEP at 26 weeks (68). Participants 
that accepted PrEP utilized a median of six C4 sessions (range 3-8) compared to a median 
of four C4 sessions (range 2-6) by participants that did not accept PrEP (68). Sixty-seven 
percent of participants self-reported adherence of greater than or equal to 90% at the end 
of the year (68). Even with tailored counseling, the proportion of participants self-
                                               
22 Protective concentration was defined as drug levels consistent with 4 pills per week. 
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reporting adherence at endline in HPTN 073 was lower than the proportion of 
participants with protective concentrations of PrEP in the Demo Project. These findings 
demonstrate that African American/Black MSM accept PrEP and counseling. However, 
despite acceptance, adherence remains a concern.    
The PATH (PrEP and Testing/linkage to care for HIV Prevention)-PrEP study 
aimed to evaluate PrEP adherence among a cohort of men who have sex with men or 
women, and transgender women enrolled from two community-based clinical sites in Los 
Angeles who received daily oral PrEP (72). Participants (n =301) received guided 
motivational counseling focused on sexual health protection and PrEP adherence at five 
visits over 48 weeks. Adherence was measured by plasma drug levels; low adherence23 
triggered an escalated adherence support approach. At endline, 68% of participants had 
protective concentrations of PrEP (72). Younger PrEP users and African American/Black 
PrEP users were significantly less likely to achieve adherence (72). Participants of color 
made up 70% of those who received escalated adherence counseling; among this group, 
50% sustained PrEP adherence after escalated counseling (72). Similar to findings from 
the Demo Project, results from the PATH-PrEP study indicate that participants of color, 
as well as younger participants, may require stronger or better tailored adherence support. 
Project PrEPare (ATN 110) provided PrEP and evidence-based HIV prevention 
interventions to young MSM for 48 weeks. Prior to initiating PrEP, participants received 
an evidence-based HIV prevention intervention. After initiation, participants received 
                                               
23 Low adherence was defined as having TFV-DP levels above the lower limit of quantitation (10 
ng/mL). 
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sexual health promotion and adherence counseling at each visit. Participants (n = 200) 
were enrolled from 12 urban sites in the US (73). Over 90% of participants reported the 
counseling and the study overall as acceptable (74). As measured by DBS, a majority of 
participants had protective concentrations of PrEP during the first 12 weeks, but by week 
48, this proportion decreased to 28% of participants (74). African American/Black 
participants’ median levels of PrEP were below the protective threshold throughout the 
study (74). These findings echo findings from the other demonstration projects, 
suggesting that adherence support is needed for young MSM, and young African 
American/Black MSM in particular.  
Though these demonstration projects did not focus on WOC, they offer useful 
insights into PrEP provision. These projects showcase comprehensive PrEP care that, in 
addition to following PrEP clinical guidelines, provided client-centered care (i.e., how 
PrEP fits into their own care plans, or culturally-tailored counseling), and linkages to 
other social services as needed. Age and race disparities exist in PrEP adherence. Though 
MSM of color appear to accept targeted adherence counseling and PrEP, adherence was 
low in this group. In the three demonstration projects that included both African 
American/Black and non-African American/Black participants, the former group was less 
likely to have protective concentrations of PrEP compared to their peers. This finding 
was particularly evident in Project PrePARE, in which young African American/Black 
MSM participants never achieved protective levels of PrEP during the course of the 
study. Tailored adherence counseling, such as the C4 counseling provided in HPTN 073 
or the escalated adherence counseling provided in PATH-PrEP, appeared to boost 
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adherence. When considering PrEP implementation for WOC, health care workers will 
need to understand not only if WOC find PrEP acceptable, but how to translate 
acceptance into uptake and support PrEP adherence.  
2.3.2 Other PrEP care models 
Though many health centers and clinics offer PrEP, there is limited published 
literature examining PrEP specifically for women. Through a literature review, I 
identified two formal PrEP care models for women. Though these programs did not focus 
on WOC, they are useful starting points when considering how to best implement PrEP 
for WOC. 
Seidman et al. (2016) retrospectively examined PrEP provided in two specialty 
clinics for women living with or at substantial risk of HIV (75). These clinics were 
housed within academic medical centers: one clinic was co-located in an obstetrics clinic, 
and the other was co-located in an infectious disease clinic (75). Both of these clinics 
utilized multidisciplinary teams and provided case management, safer conception 
counseling, and reviewed HIV prevention options (75). Providers identified 27 women at 
substantial risk for HIV preconception according to the USPHS guidelines (75). Women 
were 19% African American/Black and 44% Hispanic (75). The most common HIV risk 
factor was having a HIV-positive male partner; women served in these clinics often did 
not know the sexual behaviors of their male partners (75). Fifty percent of women on 
PrEP experienced challenges including nausea, fatigue, and difficulty adhering to a daily 
pill, and 40% of women chose to stop PrEP after conception or delivery (75). Findings 
from this retrospective review demonstrate that antenatal care is an opportunity to 
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identify women eligible for PrEP. Further, women are interested and motivated to take 
PrEP; however, women’s choices may change as they navigate peri-conception, 
pregnancy, and breastfeeding. 
Blackstock et al. (2017) described the experience of a community-based sexual 
health clinic integrated within a large health system in the Bronx, New York City (76). 
Retrospective chart review revealed that of the 554 HIV-negative women who received 
care at the clinic, 21 (about 4%) were prescribed PrEP (76). With a median age of 35 
years, women prescribed PrEP were mostly WOC and had public health insurance (76). 
Of the 21 women prescribed PrEP, 18 were in a known serodiscordant relationship (76). 
Eleven women were retained in PrEP care at three months, and six were retained at six 
months (76).24 This review show that providers were most likely to identify women with 
sexual partners living with HIV as PrEP candidates. Further, the review does not describe 
how or if patients were provided adherence support, but the low adherence at three and 
six months suggests that adherence challenges exist.  
From these care models, two key considerations are useful for PrEP 
implementation for women. First, most women in these settings were identified as PrEP 
candidates because of a known HIV-infected male partner (96% across the obstetrics and 
ID clinics, and 85% in the Bronx sexual health clinic) (75,76). This may be because 
having a HIV-positive partner is an easily identifiable risk factor for providers, and that 
providers are not probing deeper into patients’ risk factors. These findings indicate that 
                                               
24 Denominators for three months (11/18) and six months (6/16) include only those with sufficient 
follow-up time from PrEP initiation.  
  29 
there were missed opportunities to speak with women about PrEP and that providers may 
not be comfortable or properly equipped to assess women’s eligibility for PrEP. Second, 
these experiences demonstrate that adherence support needs to be a part of 
implementation. In the specialty clinics, 50% of patients reported having a challenge with 
adhering to PrEP (75). In the Bronx sexual health clinic, adherence was only 37.5% at six 
months follow-up (76). Similar to findings from the demonstration projects, in which 
adherence was a challenge for young participants and participants of color, female 
patients in these identified reviews struggled with adherence. Adherence support for 
women is needed, though these reviews did not identify any strategies.  
2.4 Review of available PrEP implementation guidance 
 
To support the second aim of developing recommendations for PrEP 
implementation, I conducted a review of available PrEP implementation guidance.  
I defined guidance broadly as any document, manual, tool, commentary, or checklist 
developed for PrEP implementation. The existing guidance documents provided by major 
sources are summarized in Table 3 below. The WHO guidance describes care issues by 
type of staff, recognizing that a comprehensive PrEP program requires clinical and non-
clinical support (e.g., care navigators) (77). The New York State plan and the WHO tool 
importantly describe logistical concerns for PrEP implementation (77,78). The New York 
State plan, which informed DC’s 90/90/90/50 plan, includes an Electronic Medical 
Record (EMR) template for risk assessment that may be a useful starting point to adapt 
for PrEP implementation for women. The King County and the Fenway Institute 
resources contains summary guidance, mostly focused on clinical guidelines, for 
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providers. HIVE’s toolkit provides insight on how staff can engage in women-centered 
shared decision-making along with operational resources (79,80). Finally, Aaron et al.’s 
(2018) systematic review recommends how providers can identify women at risk for HIV 
and provide PrEP and client-center HIV prevention care to women (81). In sum, these 
guidance detail operational and clinical aspects of PrEP, as well as consider women-
specific considerations for PrEP implementation. 
Table 3. Review of available PrEP implementation guidance 
Guidance material Lessons for PrEP implementation for women 
WHO Implementation Tool 
for PrEP of HIV Infection 
(77) 
- Published: July 2017 
- Focus population: General 
- This tool discusses the need for a culturally-sensitive 
approach for adolescent, young adult, and adult 
women, as their needs and concerns are different 
from men, and encompass changing reproductive 
health needs. The tool outlines women-centered 
PrEP counseling that focuses on enabling women to 
have informed and voluntary choice of HIV 
prevention options. 
Seattle, King County, & 
Washington State Department 
of Health PrEP 
Implementation Guidelines 
(82) 
- Published: 2015 
- Focus population: General 
- This brief article discusses considerations for PrEP 
implementation guidelines. The article includes a 
one-pager with user-friendly guidelines for medical 
providers on who should be approached about PrEP 
initiation, and promotes a shared decision-making 
process in which providers routinely discuss PrEP 
with patients. 
Fenway Institute, Introducing 
the "PrEP Package" for 
Enhanced HIV Prevention: A 
Practical Guide for 
Clinicians (83) 
- Published: 2012 
- Focus population: 
Clinicians 
- This tool details a patient-centered process for PrEP 
counseling, initiation, and retention that includes 
adherence assessment, and safer-sex counseling. The 
tool discusses the need for patients to be offered a 
selection of HIV prevention services (“PrEP 
package”), developed from individualized risk 
assessments.  
New York State Targeted 
PrEP Implementation (78) 
- Published: 2016 
- Focus population: MSM 
- This is a report of state-wide implementation plan, 
and it includes a risk assessment tool (EMR 
template), patient survey, and infographics on 
components of PrEP implementation (e.g., 
infrastructure, quality assurance, data reporting, 
lessons learned). 
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Table 3. Review of available PrEP implementation guidance 
Guidance material Lessons for PrEP implementation for women 
HIVE’s Family Planning 
Provider PrEP Toolkit (79) 
- Published: 2016 
- Focus population: Women 
- This web-based toolkit compiles existing tools and 
resources to support family planning clinics in 
providing PrEP. Included within are resources on a 
shared-decision making, an operations checklist, and 
clinical guidelines. This toolkit also includes 
Seidman and Weber’s (2016) commentary on how to 
integrate PrEP into women’s health care that offers a 
conceptual model of HIV risk factors for women and 
insight into taking a women-centered approach into 
shared decision-making between provider and client 
(80). 
Optimizing Delivery of HIV 
Pre-exposure Prophylaxis for 
Women in the United States 
(81) 
- Published: 2018 
- Focus population: Women 
- This article reviews available evidence related to 
PrEP implementation for women including 
individual and systematic barriers. 
Recommendations on how to provide care are given 
including practicing shared decision-making; 
assessing HIV risk over time rather than at one point 
only; and what topics should be included in PrEP 
counseling. This article also includes an assessment 
to identify women who may benefit from PrEP and a 
clinical roadmap from PrEP screening through 
follow-up visits.  
 
 
2.5 Women of color and providers’ perspectives on PrEP  
 I used three bibliographic databases (PubMed, Web of Science, and Google 
Scholar) and databases from key conference related to HIV to review the literature on 
WOC and providers’ perspectives on PrEP (inclusion dates: January 2012 – October 
2019). I identified 50 peer-reviewed publications that included WOC25 and providers’26 
perspectives on PrEP (20 publications and 30 publications, respectively). 
                                               
25 In each of these studies, African American/Black and Hispanic/Latina women made up a majority 
of the sample populations. 
26 None of these studies focused on providers’ perspectives as they related to PrEP for women 
specifically, though one study examined PrEP as related to safer conception (114). 
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2.5.1 Women of color’s perspectives on PrEP use   
Many women reported that they did not know about PrEP. Surveys have shown 
low levels of awareness of PrEP among WOC. A 2013 survey of over 600 WOC in New 
York City found that only 12% knew about PrEP (84). Similarly, a 2014-2015 survey of 
225 women (96% identified as WOC) in the Southern US found that only 11% had heard 
of PrEP (85). More recently, surveys among WOC in Philadelphia (2017; n =389) and 
Chicago (2018; n = 370) have found higher levels of PrEP awareness, at 27% and 30%, 
respectively (86,87).  
 A 2017 survey of women (n = 501) in three urban cities found that African 
American/Black women were less likely than White women to know about PrEP (28.1% 
v. 19.9%, respectively) (88). Similarly, a retrospective study reviewing patient intake 
forms from 2013-2016 at a Rhode Island STI clinic found that PrEP awareness was 
significantly lower among Hispanic women and non-Hispanic Black women compared to 
non-Hispanic White women (11% and 14%, v. 21%, respectively) (89). Qualitative 
studies of WOC in US cities confirm this lack of awareness, with many participants 
stating that they were not aware of PrEP before participating in the study (19,90–93). 
Women expressed frustration and feeling upset that they had not been made aware of 
PrEP (90,91,93). Some African American/Black women perceived that they are not made 
aware of PrEP because they, as WOC, are not valued in society (93). Most women who 
reported knowledge of PrEP only knew about PrEP in the context of HIV prevention for 
MSM (84,91,93,94). 
Women of color may not perceive themselves to be at high risk for HIV infection. 
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In a survey of over 2,100 women, primarily African American/Black women, only about 
8% believed themselves to be at moderate or high risk for HIV infection, whereas trained 
study assessors identified 60% of the participants to be at moderate or high risk (95). In 
two samples of young African American/Black women in Atlanta, 16% and 20% of 
participants who screened positive for a STI did not report any risk factors for HIV, 
respectively (96,97). One study found that participants with higher perceived risk for HIV 
were more interested and accepting of PrEP than those with lower perceived risk (96). 
However, Garfinkel et al.’s 2017 survey of young women (n = 146) at a family planning 
clinic showed that although women were worried about HIV, this worry was not 
associated with PrEP acceptability (98). These findings are similar to those from the 
VOICE and FEM-PrEP trials, in which participants discussed a lack of interest in PrEP 
due to their low perceived risk for HIV (50–52). 
Women described PrEP use as a potential burden, stating that they were already 
burdened with the responsibility of birth control and that using PrEP as well as condoms 
to prevent other STIs would be too much of a burden (93,94). Other women described 
that the frequency of medical visits, lab testing, and prescription refills required for PrEP 
as too burdensome (92,94). Some thought remembering a daily pill would be difficult, 
though others thought the daily dose would promote adherence (90,92,94). Women 
voiced worry about how they might pay for PrEP, wondering why they would pay for 
PrEP when condoms are accessible for free (19,91,93,94).  
Women cited the potential side effects from PrEP as a concern. Women were 
concerned about PrEP’s possible interactions with other drugs, how PrEP might affect 
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their organs, and how PrEP might affect their sex drive (93–95). Women were wary that 
unknown side effects may exist, given that PrEP is a relatively new medication (19,90). 
Some wondered if experiencing side effects from PrEP was worth taking PrEP given that 
it is not treating a disease and that other options, such as condoms, are available without 
side effects (19,91).  
Women also worried that PrEP use may cause some women to increase risky 
sexual behavior; that is, because they feel PrEP is protecting them from HIV, they may 
increase their engagement in riskier behaviors. In focus groups of WOC in New York 
City, participants stated that women may feel that they do not need to use a condom 
because of the protection PrEP provides (94). Older women said that PrEP use would 
increase “promiscuity” among younger women because the younger women would not 
realize they were still at risk (92). Similarly, in focus groups of mother-daughter dyads, 
mothers expressed concern that young women might engage in riskier behaviors if on 
PrEP (90). Additionally, some WOC wondered if PrEP use may dissuade conversations 
with partners about their sexual behaviors, therefore increasing a woman’s risk (19). 
Participants in another study cited concern that PrEP use might encourage women to 
remain in unhealthy or abusive relationships, using PrEP’s protection to excuse or not 
address the problems that drove them to take PrEP (94). 
Women of color described a mistrust of pharmaceutical companies, the medical 
system, and providers as potential barriers to PrEP uptake (88,90). Women voiced 
suspicion that PrEP could be a money-making “ploy” by pharmaceutical companies (19). 
Women were concerned about being used as “guinea pigs” by the medical system, 
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connecting this worry to the historical traumatic experiences of the African American 
community caused by the medical system (e.g., the Tuskegee syphilis experiment) 
(19,93). One women explained that she was hesitant to trust any medication “specifically 
targeted at a particular demographic” (94). Though women identified their providers as a 
trusted source of medical information generally, they wondered why their providers did 
not inform them about PrEP. This led some women to not trust that their providers knew 
enough about PrEP or women’s sexual health, and view providers as unreliable sources 
of information regarding HIV prevention (92,93). 
  Women were also concerned about the possible stigma surrounding PrEP. 
Women stated that having PrEP listed on their insurance and pharmacy records, making 
multiple visits for PrEP care, and discussing sexual behavior with their physicians would 
be stigmatizing (92,94). Some women thought that people would not understand that 
PrEP was for prevention, and would therefore think that women who use PrEP are HIV-
positive or are sexually promiscuous (93). Women associated the stigma attached to PrEP 
with the stigma related to HIV or finding out that someone was on ART for HIV (90,93).   
Despite WOC identifying many potential barriers to PrEP uptake, in many studies 
WOC generally accepted PrEP and described potential benefits of its use (90,93,94,96). 
These benefits included that PrEP could be a woman-controlled method and an option for 
women with higher-risk or serodiscordant partners, and that having the choice to use 
PrEP could be empowering (92,94). A 2014 survey of Southern WOC found that 77% 
expressed willingness to consider using PrEP (85). Other research demonstrates that 
WOC are more interested and have greater intention to use PrEP than White women 
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(88,98). In a qualitative study of serodiscordant African American/Black couples in 
Boston who utilized PrEP, participants described that PrEP increased the intimacy and 
strength of their relationships (58). In a separate focus group of African American/Black 
women in Boston, one participant stated that PrEP is “a great way to help women, 
particularly Black women, take care of their health” (94).  
2.5.2 Providers’ perspectives on PrEP  
Research demonstrates that there is a lack of knowledge about PrEP among 
providers. A national survey of primary care providers (PCPs) found that PrEP awareness 
increased from 24% in 2009 to 66% in 2015, but that PrEP knowledge was limited, with 
only 22% of providers reporting that they had read the USPHS’s 2014 clinical guidelines 
(99). Walsh et al. (2017) reported that 75% of PCPs in their survey were aware of PrEP 
(100). Of those PCPS who were aware of PrEP, they answered an average of 67% of 
PrEP knowledge questions correctly (100). Psomas et al. (2019) found that though 79% 
of ED providers reported that they had heard of PrEP, only 24% were aware of the 
current clinical guidelines (101). Research demonstrates that greater PrEP knowledge is 
associated with a greater willingness to prescribe (102), higher intention to prescribe 
(103), a more positive attitude about PrEP (104), and more PrEP-related discussion and 
prescribing (100,105,106). 
Providers expressed a variety of beliefs about who is best positioned to prescribe 
PrEP. Both HIV and non-HIV providers stated concern about the feasibility of providing 
PrEP in primary care settings due to time constraints and lack of specialized training 
(e.g., sexual history taking, experience in ART care, and lack of counseling services) 
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(107,108). Yet, some providers argued that PrEP should be provided in a primary care 
setting as HIV-negative individuals are more likely to access care at primary care centers 
(107–110). Both HIV and non-HIV providers have expressed concern that they were 
unable to effectively identify patients who would be good candidates for PrEP and to 
counsel them on risk reduction (107,111). In a 2014-2015 national survey, fewer PCPs 
than HIV providers were aware of PrEP and felt comfortable with PrEP-related behaviors 
(e.g., sexual history taking, PrEP prescribing) (112). Krakower et al. (2014) describes this 
problem as the “purview paradox”: neither HIV specialists nor PCPs believe PrEP 
prescribing to be within their purview (107). Both HIV and non-HIV providers identified 
the lack of training as a barrier to PrEP implementation, requesting more training in 
adherence counseling, screening and selecting patients for PrEP, managing side effects, 
risk reduction counseling, and advising on PrEP and conception (99,109,113–115). 
Providers report clinical concerns about PrEP. Both HIV and non-HIV providers 
have cited the possibility of developing drug resistance (101–103,109,110,116) and 
possible drug toxicities (103,107,110) as concerns when prescribing PrEP. In a 2012 
study of HIV and non-HIV providers in South Carolina and Florida, 88% of providers 
agreed that PrEP could promote development of resistance if used as monotherapy (102). 
Concerns about drug toxicity may be associated with limited willingness to prescribe 
PrEP (103). HIV and non-HIV providers also cite side effects, such as nausea and 
headaches, as an additional clinical concern (101,106,109).  
Providers worried about how patients would pay for PrEP. In three provider 
surveys, 36% (HIV and non-HIV providers), 57% (ID providers), and 96% (providers 
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from STI/family planning clinics), respectively, cited cost to the patient as a concern 
(102,103,110). This concern also arose in focus groups of HIV providers in Boston (107). 
HIV providers stated that the need to pull multiple resources together to ensure financial 
coverage of PrEP was burdensome (114). In a national survey of over 700 providers, 
28.7% and 12.1% of providers from various disciplines reported that being unable to 
receive prior authorization and insurance denials, respectively, had prevented them from 
prescribing PrEP (117).  
Providers are concerned about patients maintaining adherence to PrEP. Among a 
sample of HIV and non-HIV specialists in the San Francisco region, 58% expressed 
concern about their patients’ ability to maintain adherence to PrEP (109). Likewise, 40% 
of providers (both HIV and non-HIV providers) cited adherence as one of their top three 
concerns with PrEP prescribing (103). A national survey of ID providers found that 77% 
worried about PrEP adherence (110). This concern was also apparent in qualitative 
studies of HIV providers and non-HIV providers (114,118,119). Both HIV and non-HIV 
providers have stated the need for long-term monitoring of patients as a potential barrier 
to PrEP implementation, affecting their willingness to prescribe PrEP (103,108,120,121).  
Some providers believed PrEP would lead to increased risky sexual behaviors, 
such as lack of condom use and greater numbers of partners (111). In qualitative 
interviews, HIV providers said that they worry their patients would experience a false 
sense of security while on PrEP, leading to risky behaviors and increased risk for HIV 
(107). A 2016 US-wide survey of HIV providers working with serodiscordant couples 
had similar findings (114). Providers’ views on risk compensation may be changing as 
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awareness about PrEP increases and more patients seek out PrEP care. A 2017 qualitative 
study of providers who had PrEP prescribing experience (most of whom were HIV 
providers) found some providers who were initially concerned about risk compensation 
later became skeptical that this was an actual concern (122). Some providers described 
that they were not seeing an increase in risk behavior, while others believed that PrEP 
provided enough benefit even with increased risk behavior (122).  
Providers’ willingness to prescribe may differ by patient group. A 2014 survey of  
HIV providers found that they were most willing to prescribe for MSM who have an 
HIV-positive partner while being least willing to prescribe to high-risk heterosexuals or 
people who inject drugs (120). Previous surveys show a range in the proportion of 
providers willing to prescribe PrEP to women: 60% among HIV-providers; 87-89% 
among internal medicine providers; and 92% among HIV and non-HIV providers 
(109,123,124). A study examining PrEP prescribing at a community-based sexual health 
center found that most women on PrEP reported that they were in serodiscordant 
partnerships (76). This suggests that providers may not be reaching women at high risk of 
HIV including those who do not know their partners’ serostatus (76). A computer-
administered experiment conducted with medical students examined their willingness to 
prescribe by patient’s race (125). These students rated African American/Black patients 
as more likely to engage in risky behavior while on PrEP, and therefore medical students 
were less likely to prescribe PrEP to this patient group (125).  
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2.5.3 Summary of literature 
Women make up nearly one-fifth of new HIV infections in the US, yet few are 
being informed about PrEP. Many WOC reported that they had heard about PrEP for 
MSM, but they did not know that PrEP was an option for themselves. This lack of 
awareness caused women to feel frustrated and unvalued. Despite the many potential 
barriers to PrEP uptake, WOC generally find PrEP acceptable and identify it as a 
potentially powerful tool for HIV prevention. Particularly in high incidence areas, efforts 
are needed to inform women that PrEP can be part of their HIV prevention options. 
Providing this information could also build trust with their providers, reduce the stigma 
associated with PrEP, and allow women to better understand side effects and their HIV 
risk. 
Providers may be under-equipped to prescribe PrEP. Awareness of PrEP has 
increased in the last several years, but this has not resulted in changes in clinical practice. 
This may be because providers – both HIV and non-HIV providers - require more 
training on topics related to PrEP such as medication side effects and toxicities. In 
particular, there is a need for more providers to learn how to take sexual histories and to 
provide adherence and risk reduction counseling, especially to reach all women at 
substantial risk across different care settings.  
WOC voiced a lack of trust in the medical system as a major concern. Abuse and 
racism within the US medical system against people of color are well-documented (126–
130). WOC have been forcibly sterilized and forced to undergo medical procedures 
without their informed consent or against their wishes (131–134). Kaiser Family 
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Foundation’s 2009 report of state-level health indicators found that WOC fared worse 
than White women in almost every state, with some of the largest disparities seen in rates 
of new AIDS diagnoses and lack of prenatal care (135). The Institute of Medicine’s 2003 
review Unequal Treatment reported that providers’ bias in decision-making (such as 
prescribing fewer medications and providing lower levels of treatment to people of color 
compared to White people) is a significant contributor to racial and ethnic disparities in 
health care for both men and women, citing treatment differences in cancer, coronary 
heart disease, and HIV/AIDS (130). Though there is not much research on provider PrEP 
prescribing practices, the limited research shows that there may be racially discriminatory 
prescribing practices (125). The lack of knowledge about PrEP and the low uptake of 
PrEP among WOC may also be a result of provider bias or assumptions regarding who is 
eligible for PrEP. One practice that may decrease the disparity in PrEP prescribing and 
counteract potential provider bias would be routinizing PrEP for women; that is, 
incorporating PrEP education and counseling into all women’s routine health care visits.  
Medical providers and WOC identified some similar concerns about PrEP, 
namely cost, adherence, and the possibility of risk disinhibition. The cost of PrEP may 
indeed be a significant barrier as Truvada costs nearly $2,000 per month, in addition to 
costs for laboratory tests and office visits prior to initiation and during care (136,137). 
Medicaid covers PrEP, but for those with private insurance, out-of-pocket expenses for 
laboratory tests, clinic visits, and medication vary and be burdensome (136,138). 
Although private insurance typically provides at least some coverage for PrEP, several 
insurance plans have large deductibles or copays (111). Some states have developed 
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patient assistance programs or care support programs, but these may not cover the cost of 
the drug and care (111). Gilead Sciences has a medication assistance program for patients 
making less than 500% of the federal poverty line (139). Even with these programs, the 
reimbursement process requires significant documentation and the ability to negotiate a 
complex process, often over the course of multiple office visits (111). In DC, the DOH 
offers a drug assistance program (DAP) for PrEP for insured and uninsured DC residents 
(140). PrEP DAP pays the monthly co-pay and deductible for the medication, but funding 
is limited and does not cover laboratory work or office visits (140). Patients and their 
provider must complete an application form that includes indicating HIV risk behavior 
(e.g., “a sexual relationship with a person living with HIV”), which some patients may 
find stigmatizing (140). However, the US Preventive Services Task Force’s recent grade 
A recommendation of PrEP will require insurance plans to provide PrEP at no cost-
sharing for patients beginning in 2021 (141). 
Adherence is also a significant barrier. As clinical trials indicate, women need to 
maintain at least 75% daily adherence in order for PrEP to be effective (53). Adherence 
support requires thoughtful, patient-centered, ongoing discussions between women and 
providers on how women can feasibly integrate PrEP into their lives. Regarding the 
concern that PrEP use will lead to an increase in risky behaviors, cited by both WOC and 
providers, most evidence does not support this concern. The TDF2 clinical trial, which 
was exclusively women, did not find evidence of increased risky behaviors (49). A 2016 
systematic review found that there was no change in condom use or an increase in 
condom use over time when comparing PrEP users to non-PrEP users (142). Similarly, 
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this review found that the number of sexual partners either did not change or decreased 
from baseline when comparing PrEP users to non-PrEP users (142). However, though the 
Partners PrEP trial showed a decrease in risky behaviors, there was an increase in number 
of non-primary sexual partners after participants were unblinded (143). Notably, these 
studies typically included risk reduction counseling. As these results may not be 
generalizable to WOC in the US, more research in this area is needed.  
2.6 Discussion  
There is very limited information available about how to provide PrEP for women 
and, more specifically, WOC. There are no completed or ongoing US demonstration 
projects that focus on women. Of the PrEP programs identified, two focused on women. 
Findings from these care models focused primarily on program indicators (e.g., the 
number of women who initiate PrEP) rather than on best practices for providing care to 
women (75,76). Understanding the operations and processes that need to be in place to 
implement PrEP successfully are needed to inform future program development. With the 
exception of HIVE’s Family Planning Provider PrEP Toolkit and Aaron et al.’s 
systematic review, there is little published guidance on PrEP implementation for women 
(79,81). Notably, these resources highlight care areas that are not addressed in the 
demonstration projects, such as a women-centered approach that a focus on choice and 
shared decision-making as well as integrating reproductive goals into HIV prevention 
(76). The literature review revealed that WOC have multiple concerns about PrEP, 
including perceiving PrEP as a burden, mistrust in the health care providers, and the 
stigma associated with taking PrEP. Women-centered care would address these concerns. 
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Lack of adherence is a major challenge to PrEP care cited throughout the 
literature, including in the clinical trials. WOC have cited adherence, and the overall 
burden of a daily medication, as a potential barrier to PrEP use (92–94). Though the 
demonstration projects did not focus on women, these projects showcase care 
components that may support adherence: client-centered counseling that discusses 
facilitators and barriers to adherence, discussion about how PrEP fits into a patient’s plan 
for HIV prevention, and culturally-tailored support that addresses other social needs 
(67,68). PrEP provision for women should consider how to ensure space for women’s 
unique health concerns and lived experiences (e.g., intimate partner violence), with an 
emphasis on developing feasible, individualized adherence plans, and providing 
adherence support. 
A comprehensive PrEP care model for WOC would likely include a process for 
identification of patients engaging in behaviors that put them at risk for HIV, same-day 
initiation or a linkage to care system with follow-up, dedicated staff to provide adherence 
and risk reduction counseling, and providers who monitor and are knowledgeable about 
patient risk. Tools and skills that support women-centered care, such as EMR templates 
that include questions about their reproductive plans and counseling that encourages 
shared decision-making, are needed to support implementation. Efforts that engage with 
WOC to increase their knowledge of HIV risk behaviors and PrEP as an option for them 
for HIV prevention are also needed. Similarly, efforts to increase PrEP knowledge and 
competency of PrEP-related behaviors among providers are warranted. A 
multidisciplinary team to provide supportive services, including benefits navigation that 
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allows patients to better understand their costs, would likely enhance PrEP 
implementation for women. As PrEP implementation increases the burden on clinic 
systems, a mechanism for evaluation and feedback from patients and staff to identify 
challenges and opportunities and incorporate quality improvement is needed. Finally, as 
best care settings and processes for PrEP implementation for WOC are still being 
identified, clinics will need to be both flexible and innovative in adapting to changes as 
needed.  
The real world experiences of providing PrEP to WOC are missing from the 
literature due to the lack of PrEP for WOC programs. Though this dissertation does not 
include WOC’s perspectives on PrEP, it provides an in-depth examination of the 
implementation of a PrEP for WOC in three different clinical settings. I used findings 
from this chapter, in addition to the theoretical framework described in Chapter 3, to 
develop an interview guide examining implementation from the perspectives of clinic 
staff and providers. For example, I asked interview participants to describe the process 
and tools used to engage women about PrEP. Finally, I attempted to identify strategies 
that may support and improve PrEP implementation for WOC through this literature. I 
used this review, combined with data collected for this study, to develop 
recommendations for the implementation of evidence-based, effective, and tailored PrEP 
for WOC implementation, as discussed in Chapter 5.  
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CHAPTER THREE: RESEARCH DESIGN AND METHODS 
3.1 Chapter overview 
This chapter provides a detailed description of the dissertation’s study design and 
methods. First, I discuss the research approach and conceptual framework that guided the 
development of the aims, design, and methods. Next, I describe the data collection and 
analysis methods for each aim.  
3.2 Research approach and conceptual framework 
3.2.1 Case study approach 
The case study approach was selected for this project in order to examine the PWI 
in a real world context; that is, to examine the initiative as it is happened naturally. Rather 
than an experimental design which attempts to test a specific hypothesis by controlling or 
manipulating variables of interest, a case study approach allows for information to be 
captured on exploratory questions (e.g., how was PrEP implemented, and how did staff 
and providers view PrEP implementation?) and provide insight into implementation gaps 
(38,43). The case study approach is flexible and can explore, describe, or explain 
phenomena (43,144). Case studies provides a holistic understanding of the multiple 
factors impacting implementation, and uses theory to drive data collection and 
interpretation (39). Case studies have been used in health services research to examine 
program implementation, offer ideas for quality improvement, and develop public health 
programs (38,145). This dissertation includes three case studies that examine factors 
impacting PrEP implementation for WOC. 
Crowe et al. (2011) built from Yin’s work and identified five main stages of case 
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study research activities: 1) case definition; 2) case selection; 3) data collection; 4) data 
interpretation; and 5) reporting of findings (38,43). For case definition, researchers 
should employ a theory-driven approach to ensure a detailed examination with a clear 
scope and timeframe to define the case (38). For case selection, the researcher must 
consider access to the site and the staff, and the burden of study participation on the site 
(38). Case selection may be out of the researcher’s control, if selection has been decided 
by a key stakeholder (38). For data collection, case studies typically employ mixed 
methods with an emphasis on qualitative data to provide detailed insight on the program 
or process being studied, including open-ended surveys, interviews, and document review 
(38,43). Data interpretation should allow for data to be organized and coded according to 
key themes developed from theory or emerging organically from the data (38). Finally, 
when reporting the findings, researchers need to provide enough contextual information 
to understand the phenomena, while also protecting confidentiality of sites and 
participants (38). The five main stages of case study research as related to this study are 
described in Table 4 below.  
Table 4. The five main stages of case study research for the PrEP for Women Initiative 
implementation study  
1. Case 
definition 
The case as defined for this dissertation was the health clinic 
implementing PrEP for WOC in Washington, DC (three cases in total). 
2. Case 
selection 
The cases for this dissertation were pre-selected by two key 
stakeholders, DC DOH and WAP. These cases represented, 
respectively, a hospital ED, a FQHC, and a community-based non-
profit clinic. These cases were selected by DC DOH and WAP based 
on their demonstrated experiences providing health care for WOC. 
3. Data 
collection 
The primary data collection method was one-on-one semi-structured 
interviews. Review of administrative data, site documents, and 
published literature was also used. Data collection is described further 
in section 3.3.2. 
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Table 4. The five main stages of case study research for the PrEP for Women Initiative 
implementation study  
4. Data 
interpretation 
Qualitative data analysis was conducted using the Framework Method 
(described in section 3.3.1.1). The complete data analysis plan is 
presented in section 3.4.  
5. Reporting 
the findings 
Chapter 4 reports the findings and Chapter 5 discusses the findings. 
Additionally, findings will be reported through a peer-reviewed 
publication. Data dissemination is described in section 3.5. 
 
3.2.2 I-PARIHS conceptual framework 
Implementation science (IS) is the “study of methods to promote the uptake of 
research findings into routine practice” (146, p.491). IS is concerned with knowledge 
translation; that is, the transfer of evidence into clinical practice in order to improve 
patient care and outcomes (147,148). The primary focus of IS studies is not on the effects 
of the intervention but rather examining the processes, policies, and contexts that 
influence implementation (149). IS frameworks provide a set of defined constructs to 
organize and describe concepts, information, and data without defining a causal 
relationship (150).  
The Promoting Action on Research Implementation in Health Services (PARIHS) 
framework was originally conceptualized to understand successful implementation of an 
evidence-based intervention as a function of the quality and type of evidence, the context, 
and how the evidence was facilitated in practice (44). The PARIHS framework has 
guided more than 40 IS studies, including naloxone distribution at a safety net hospital, 
HIV testing at Veterans Affairs clinics, and an effort to establish a partnership between 
an academic institution and a rural health care setting (44,151–153). However, upon 
critical feedback and review, the framework developers determined that the PARIHS 
framework did not include a construct that emphasized both those who facilitate and 
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those who receive the implementation, and did not take into account the possible effects 
of the external context (44).  
In 2014, the PARIHS framework was updated and expanded into the integrated-
PARIHS (i-PARIHS) framework. This updated framework draws from multiple theories 
such as Rogers’s Diffusion of Innovations Theory (1995); Weiner’s Theory of 
Organizational Readiness to Change (2009); and Plsek and Greenhalgh’s Complexity 
Theory (2001) (154–156). The framework examines four core constructs: 1) facilitation: 
how does implementation happen, that is, the process of navigating individuals and teams 
through change and challenges; 2) innovation: what is being implemented, that is, the 
focus of the implementation effort (here, PrEP); 3) recipients: who is involved in the 
implementation, such as those who affect and enact implementation at the individual and 
collective team level (here, clinic staff and providers); and 4) context: where does the 
implementation occur, including both factors within the inner context (the clinic) and 
outer context (wider health system or health policy) that can enhance or constrain 
program implementation (44). Successful implementation is contingent on the facilitation 
process activating implementation through assessing and responding to the innovation 
and recipients within the specific context (see Figure 2) (44,45). The i-PARIHS 
framework informed the development of the research questions and aims, and the data 
collection and data analysis plans.  
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Figure 2. Successful implementation in the i-PARIHS framework (45) 
SI=Facn(I + R + C) 
• SI = Successful implementation: 
• Achievement of agreed implementation/project goals 
• The uptake and embedding of the innovation in practice 
• Individuals, teams, and stakeholders are engaged, motivated, and own the 
intervention 
• Facn=Facilitation 
• I=Innovation 
• R=Recipients (individual and collective/team) 
• C=Context (inner and outer) 
 
Facilitation is a process, with typically more than one individual acting as a team 
of facilitators who are responsible for the knowledge translation (147). Facilitators must 
have a keen understanding of the other constructs – the recipients, innovation, and 
context – for implementation to be successful. The facilitation process is iterative and 
fluid, not necessarily linear, with facilitators planning, implementing, assessing, and 
revising throughout the process (44,147).  
Innovation is the focus of the implementation effort, such as clinical guidelines or 
quality improvement initiatives. Here, the innovation that facilitators must thoroughly 
understand is PrEP. Important to understanding the innovation is identifying how it 
addresses the issue or problem, whether it offers any advantages or disadvantages over 
the current standard of care or process, establishing a credible evidence base, assessing 
the degree of fit within the local context, and how acceptable the innovation is to 
stakeholders (44). 
The recipients are those who are “directly involved in and affected by the 
implementation process” (45, p.53). Recipients can include clinical providers, staff, 
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patients, and other stakeholders. Here, the recipients are clinic staff and providers. For 
implementation to be successful, the facilitators must be able to identify the recipients, 
and understand if the recipients are willing and able to implement the innovation. 
Motivation and ability to change are important at both the individual and team level (44).   
Context refers to both the inner and outer context. The inner context includes the 
immediate environment of the recipients where the innovation will be implemented, such 
as a health clinic, and the organizational level, that is, the organization’s structure, 
systems, processes, and responsiveness to change. The outer context is the health system 
in which implementation is taking place, with consideration of political, economic, and 
cultural perspectives (e.g., local policies that may support or inhibit this innovation) (44). 
Table 5 describes areas of exploration per each i-PARIHS construct as related to the PrEP 
for Women Initiative. 
Table 5. I-PARIHS constructs as related to the PrEP for Women Initiative 
Facilitation Process by which PrEP is introduced and implemented in the clinic; 
training activities; program monitoring and evaluation 
Innovation Staff and provider understanding of the innovation (PrEP) and related 
processes (e.g., clinical guidelines); staff acceptance of PrEP; PrEP fit 
within current workflow and services  
Recipients Staff and provider resources, skills, beliefs, attitudes, and knowledge 
needed to implement the initiative (e.g., motivation to prescribe PrEP); 
staff and provider perceptions of patient-level barriers 
Context Organizational systems (e.g., EMR); community, system, or policy-
level factors that may influence implementation (e.g., DC’s 
90/90/90/50 plan or insurance policies) 
 
3.3 Research aims and methods 
Two research aims were developed to examine the implementation of the PrEP 
for Women Initiative from the perspectives of clinic staff and providers: 
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• Aim 1. Examine the implementation of the PrEP for Women Initiative. 
o Sub-aim 1.1. Describe each site’s progress towards initiative goals.  
o Sub-aim 1.2. Examine PrEP implementation barriers and facilitators. 
• Aim 2. Develop practice recommendations to support and improve PrEP 
implementation for WOC. 
Aim 1 sought to take an in-depth look into the implementation of the PrEP for 
Women Initiative. As achievement of program goals is one aspect of successful 
implementation according to the i-PARIHS, sub-aim 1.1 reports administrative data (45). 
Sub-aim 1.2, guided by the constructs of the i-PARIHS framework, identifies and probes 
about PrEP implementation barriers and facilitators. Aim 2 sought to support current and 
future PrEP programming through the development of relevant, actionable, and specific 
guidance. Table 6 describes the research aims with associated purposes, data collection 
plan, and data analysis method.  
Table 6. Research aims with related purpose, data collection plan, and data analysis 
method 
Aim Purpose Data collection plan 
Data analysis 
method 
Aim 1.1 
Describe each site’s 
progress towards 
initiative goals 
- Describe how much 
progress, if any, was 
made toward each site’s 
pre-established program 
goals 
- Administrative 
data 
- Descriptive 
analysis 
Aim 1.2. Examine 
PrEP 
implementation 
barriers and 
facilitators 
- Identify implementation 
barriers and facilitators  
- Understand the 
facilitation process, staff 
roles and responsibilities, 
and program context 
- Discuss strategies to 
reduce barriers and 
- Interviews 
- Site 
documents 
- Framework 
method for 
qualitative 
data 
analysis 
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enhance facilitators, offer 
opportunities for program 
improvement 
Aim 2. 
Identify strategies to 
support and improve 
PrEP uptake among 
WOC in the three 
different clinical 
care settings  
- Inform development of 
guidance to promote 
implementation of PrEP 
for women programs 
- Literature 
review (see 
Chapter 2) 
- Interviews 
- Site 
documents 
 
- Framework 
method for 
qualitative 
data 
analysis 
 
The qualitative and quantitative data were collected using a convergent parallel 
design in order to gain a comprehensive understanding of implementation (149,157,158). 
Using this design, qualitative and quantitative data were collected and analyzed 
separately during a similar timeframe. Then, findings were merged together during the 
interpretation to support or explain each other (149,157,158). There were four main 
sources of data: interviews, administrative data, site documents, and literature review.  
Interviews.  Aims 1.1 and 2: Guided by the i-PARIHS constructs of facilitation, 
innovation, recipients, and context, I developed two semi-structured interview guides to 
be administered to staff and providers (one guide for baseline interviews, and one guide 
for follow-up interviews) (Appendix A and B). Semi-structured interviews have a set of 
predetermined questions, but allow other questions to rise from the dialogue between 
interviewer and interviewee (159). By using open-ended questions and allowing for 
probing, qualitative interviews make it possible for researchers to explore themes or 
issues in-depth and in detail (160,161). Through individual interviews, interviewees can 
offer their perspective and expand on their experiences (160). For qualitative research, 
preliminary data analysis is undertaken in the early stages of data collection, which may 
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result in changes to the interview guide as more is learned about the subject (160). I field-
tested these interview guides with two women’s health providers to ensure that the 
questions were appropriate and relevant to the study focus. Table 7 details i-PARIHS 
constructs with a sample of corresponding interview questions.27 
Table 7. I-PARIHS constructs with corresponding interview questions 
Facilitation - How was the initiative developed? Who was involved in the launch 
of the initiative? How is training conducted and what is included? 
- What are the main components or activities of the initiative?  
- Who (what staff) is involved in the implementation? What are their 
corresponding responsibilities? 
Innovation - What have been the main challenges to implementing this initiative? 
- What has helped you implement this initiative? 
- What tools or materials do you use to implement the initiative? 
- How well does the PrEP for Women Initiative fit within your clinic?  
Recipients - How much of a priority is this initiative to you?  
- What are the necessary skills and training needed for your position to 
carry out this initiative? 
- What motivates you to implement this initiative? 
Context 
 
- How are staff involved in decisions that affect them? 
- What mechanisms are in place to support learning and evaluation for 
this initiative? 
- How does the wider health system, such as local or national priorities 
and policies, influence your implementation of initiative? 
 
Administrative data. Aim 1.1: Washington AIDS Partnership (WAP), the grant-
making organization, required that each site provide quarterly progress reports that 
included administrative data. These data were used to describe the results of program 
implementation, such as the number of women who initiated PrEP at each clinic. The 
program indicators are listed below in Table 8 and primarily relate to the constructs of 
                                               
27 Complete interview guides can be found in Appendix C. 
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facilitation (training), innovation (staff understanding of PrEP and PrEP-related 
processes), and recipients (staff and provider engagement). Additional data points beyond 
those required by WAP were not requested in order to decrease the burden of 
participation for study sites.  
Table 8. Administrative data collected for the PrEP for Women initiative 
 Indicator 
Program 
outputs 
- Number of providers trained in PrEP counseling and prescribing 
(facilitation) 
- Number of clinical support staff trained in PrEP counseling 
(facilitation) 
- Number of WOC provided information about PrEP (recipients, 
innovation) 
- Number of WOC provided PrEP counseling (recipients, innovation) 
- Number of PrEP prescriptions written for WOC (recipients, 
innovation) 
 
Site documents. Aims 1.2 and 2: Site documents that were reviewed included 
staff training curricula, manuals of operating procedures, outreach and education 
materials, and all-site monthly meeting minutes. These documents provided additional 
detail on facilitation activities, staff roles and responsibilities, implementation challenges, 
and how tools were leveraged to support program implementation.  
Literature review. Aim 2: The literature review conducted in Chapter 2 identified 
potential strategies, components, and processes that could be useful to integrate into PrEP 
programs for women.  
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3.3.1 Data collection and analysis 
3.3.1.2 Aim 1.1 
The project coordinator at each site collected administrative data and reported the 
data to WAP quarterly (see Appendix F for example of program report required by 
WAP). WAP then provided these data to the Principal Investigator (PI). Sites reported 
data on the number of PrEP prescriptions written for the year prior to program 
implementation to WAP in the sites’ application for program grants. I maintained the 
administrative data in a password-protected Excel spreadsheet. Site staff collected 
administrative data from January 2017 through December 2017; I received all program 
data for each site by July 2018. I reviewed the administrative data as they were provided 
and discussed any questions with the project coordinator.28  
3.3.1.1 Aims 1.2 and 2 
The program coordinator at each clinic provided a list of potential participants to 
contact for recruitment. I asked program coordinators to include both staff29 and 
providers involved in program implementation. These staff and providers included both 
facilitators and recipients, as defined by the i-PARIHS framework; that is, facilitators 
who are key to the initiative’s implementation, such as those who develop and oversee 
the program, and staff and provider recipients who are trained and involved in the 
implementation process, such as day-to-day activities. The program coordinator also 
provided site documents for review. I reviewed site documents (e.g., grant application, 
                                               
28 Site B and C had a PrEP Coordinator. As site A did not have a designated PrEP coordinator, a mid-
level staff member provided a list of potential participants.  
29 Staff include health promotion staff and clinical support staff.  
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workplans, operating manuals, and meeting minutes) for an in-depth understanding of 
each site’s implementation strategies.  
I conducted baseline interviews between August 2017 and January 2018, and 
follow-up interviews between May and August 2018. I selected this strategy (two rounds 
of interviews, baseline and follow-up) in order to examine implementation throughout the 
program lifespan, from the early stages through when the program was more developed. 
Due to staff turnover and availability, not every participant interviewed at baseline was 
also interviewed at follow-up. Follow-up interviews included both baseline participants 
as well as newly-identified participants. I stopped interviews when saturation of themes 
was reached. Across sites, I conducted 18 baseline interviews at baseline and 15 follow-
up interviews, with a total of 24 participants.30 
I conducted one-on-one interviews either in-person or over the phone to allow for 
flexibility in participation. Interview length ranged between 25-68 minutes (mean length: 
34 minutes). I asked participants to not include any identifying information in their 
answers. I gave participants a business card with my contact information (or an e-
business card if the interview was conducted over the phone). I audio-recorded interviews 
using two digital voice recorders.  
I transcribed audio recordings verbatim using Express Scribe transcription 
software. I stored recordings and interview transcripts in a password-protected folder on 
my computer. I struck any identifying information, such as names, that was accidentally 
included in the audio recording from the transcription. I assigned each participant and 
                                               
30 Chapter 4 describes the interview timeline at participants at each site.  
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their corresponding transcription a unique identifier number; no identifying information 
was included. I kept a master electronic file that linked participants’ names with their 
unique identifier number in a separate password-protected file.  
I analyzed data at the case (clinic) level as each setting was unique in its 
implementation activities and program goals. I conducted data analysis using NVivo 11 
qualitative data analysis software, guided by Ritchie and Lewis’ Framework Method, 
(162). The Framework Method, widely used in health research, is similar to thematic or 
content analysis in that it identifies commonalities and differences in data, examines 
relationships between data, and develops explanatory conclusions (163). This method 
allows data to be analyzed deductively, through pre-selected codes (e.g., implementation 
barriers and implementation facilitators) and also inductively, by leaving space for 
unexpected aspects or themes that may arise (163). I completed qualitative data analysis 
according to the five steps of the Framework Method, described below. Though five steps 
are listed, this analysis process is not linear, but rather iterative between data collection, 
analysis, and codebook development (163). A research assistant (RA) served as a second 
coder. 
1) Familiarization with the interview: After I transcribed the audio recordings 
verbatim, I compared the transcriptions to the recordings simultaneously to ensure 
that the transcriptions were completed accurately. After transcription was 
completed, I wrote a brief memo remarking on initial impressions and themes. 
2) Codebook development: The RA and I reviewed the first four transcriptions 
and discussed themes in the interviews. We compared these themes through 
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discussion and agreed upon a set of corresponding codes.  
3) Codebook application: Upon agreement of the codebook in step 2, we 
separately applied the codebook to the remaining transcripts. We met weekly to 
discuss the coding process and ensure consistency. If new themes arose upon 
reading additional transcripts, we discussed these themes. If agreed upon, we 
added themes to the codebook and applied the new themes to the previously 
coded transcripts. The codebook was not considered finalized until the final 
transcript was coded.   
4) Data charting: After all interviews were coded, I produced a summary of data 
in a matrixed output across rows (interviews) and columns (codes) using NVivo’s 
“framework matrix” tool. This matrix provided a structure to systematically 
examine the data by interview and code.  
5) Data interpretation: We explored data through discussion and completion of 
analytic memos. We reflected upon impressions of the data and thoughts about 
the analysis process through the analytic memos. These analytic memos also 
provided a trail of the research process.  
3.4 Protection of human subjects 
This study received exempt determination by the Boston University Medical 
Center Institutional Review Board (IRB). As a result of the exempt determination and in 
lieu of informed consent, the PI read participants an oral information sheet prior to their 
participation in the interviews.  
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CHAPTER FOUR: CASE STUDIES 
4.1. Chapter overview 
 
This chapter presents three case studies from the PWI. For each case study, I 
begin with a brief overview of the site, including site-specific goals established prior to 
implementation.31 Then, I report themes that emerged from interviews with site staff and 
providers related to implementation barriers and facilitators, linked to the i-PARIHS 
constructs of innovation, recipients, and context.32 Illustrative quotes are presented 
throughout the chapter with participant role (P for provider, S for staff member33) and 
participant identification number. 
4.2 Site A case study  
Site A is a community-based, non-profit health clinic that has provided family 
planning services for nearly 80 years to the Washington, DC metropolitan area. Site A is 
part of a network of over fifty affiliated clinics, and the first clinic in its network to 
provide PrEP to women (previously, site A had not prescribed PrEP to women). Site A 
established the following four goals for their first year of PrEP implementation: 1) all 
clinical (both providers and clinical support staff) and health promotion staff will be 
trained in PrEP34; 2) health promotion staff will provide PrEP information to 900 WOC 
through direct outreach; 3) providers will educate 1,600 WOC about PrEP within the 
                                               
31 I refer to the three sites as sites A, B, and C.  
32 For a full description of the study methods and data analysis, please see Chapter 3.  
33 Staff include both health promotion staff and clinical support staff. Health promotion staff include 
staff whose primary responsibilities involve health education and outreach. Clinical support staff 
include nurses, nurse technicians, and clinic managers.  
34 The health promotion lead trained health promotion staff and clinical support staff in PrEP 
counseling. A family planning specialist with experience in PrEP trained providers in PrEP counseling 
and prescribing. 
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clinic; and 4) providers will prescribe PrEP to 240 WOC.35 Site A reached goals 1 and 2, 
training all staff in PrEP and reaching over 3,700 patients with PrEP information through 
direct outreach.36 Site A did not reach goals 3 and 4. By the end of the first year, 
providers had educated 678 patients about PrEP in the clinic and had not prescribed PrEP 
to any WOC. I conducted a total of 12 interviews, with six participants at baseline and six 
at follow-up. Due to staff turnover and availability, only three individuals were 
interviewed at both baseline and follow-up for a total of nine individual participants. All 
participants were female. Participants included four health promotion staff, two clinical 
support staff, and three providers. 
4.2.1 Themes related to implementation barriers 
Five major themes emerged from the analysis related to implementation barriers. 
Grouped by corresponding i-PARIHS constructs, these themes were: 1) differences in 
understanding of the PrEP protocol among staff and providers (innovation); 2) staff and 
provider time limitations (recipients); 3) staff discomfort providing PrEP counseling 
(recipients); 4) staff and provider perception of patient-level barriers that needed to be 
addressed in implementation (recipients); and 5) managing different and changing 
priorities across departments (context). Each theme is described below. 
1) Differences in understanding of the PrEP protocol among staff and providers 
 (innovation). Despite all staff and providers receiving training in PrEP delivery, 
                                               
35 See Appendix E, Supplemental Tables 9 and 10 for a brief description and corresponding timeline 
for these components. 
36 Site A did not report demographic data for those reached via direct outreach and in-clinic education; 
therefore, it is unknown how many of these individuals were WOC.   
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understanding of the PrEP screening protocol varied. The protocol included both how 
staff were to screen patients for PrEP and what criteria staff used to assess PrEP 
eligibility. For screening, some staff reported that they used a sexual health history 
template in the Electronic Medical Record (EMR) to determine eligibility, while others 
appeared unaware that a template existed. A staff member stated, “We were never given 
an exact dialogue about how to conduct that conversation…. I just outline information 
that was given to me and answer any questions that [patients] may have” (S-505). 
Though the protocol stated that both clinical support staff and providers were supposed to 
conduct PrEP screening, in practice, this protocol was not always followed: “Put it like 
this, the [clinical support staff] weren’t really pushing it, the clinicians were more so” 
(S-509). 
Although they were trained in PrEP eligibility, staff reported wide variation in 
PrEP eligibility criteria. Some staff listed discrete criteria such as, “Women who either 
have multiple partners, or know that their partners are having multiple partners, or have 
had a recent bacterial STI” (P-502). However, others had broader views of PrEP 
eligibility criteria. For example, one staff member stated that she discussed PrEP with 
any patient “that just seem[ed] concerned about becoming HIV positive” (S-505).  
2) Staff and provider time limitations (recipients). Staff reported limited time to 
incorporate PrEP into their work due to being short-staffed. A provider explained how 
being short-staffed limited her time to focus on the initiative: "We've been short-staffed, 
and so my time has been pulled in a lot of different directions and away from this 
project” (P-502). The lack of time availability made it challenging for providers to 
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include PrEP during patient visits: “I feel like with all of the constraints on providers, 
especially at our affiliate, to see patients efficiently and quickly but also to continue to 
add in more topics of conversation is very challenging” (P-508). Health promotion staff 
reported delaying certain PrEP activities, such as incorporating PrEP information into 
their routine e-mails to patients, due to not having enough time: “But with our limited 
capacity, we had to wait until we had summer interns and a volunteer who could help” 
(S-503).  
3) Staff discomfort providing PrEP counseling (recipients). Health promotion and 
clinical support staff described feeling uncomfortable counseling patients about PrEP, 
despite receiving training. Staff wanted to provide PrEP counseling in a considerate 
manner, but felt under-equipped: “It’s really hard to talk to people about PrEP without 
making them feel uncomfortable, or disrespecting them in some way by suggesting that 
they are promiscuous or what have you” (S-506). One staff member reported that as a 
result of this discomfort, “We haven’t done a real push because it’s been kind of 
sensitive” (S-509). Another staff member suggested that staff training should focus on 
what language to use in PrEP counseling: “I think that if we had a little bit more training 
on how to conduct that dialogue, or stay away from words that concern or feed into the 
stigma of HIV, or I guess more training on providing comfort on usage of PrEP” (S-505).  
4) Staff and provider perception of patient-level barriers that needed to be 
addressed in implementation (recipients). Staff perceived a number of potential patient-
level barriers to PrEP uptake that arose during their conversations with patients. These 
potential barriers included limited patient knowledge about how HIV is transmitted; fear 
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associated with HIV; weighing the benefits of taking PrEP when not always needed; and 
the time burden of PrEP care. Staff perceived that patients had limited knowledge of HIV 
transmission, which made it more challenging to discuss PrEP. Staff had not expected 
that they would first need to provide basic education on how HIV is transmitted prior to 
informing women about how PrEP can be used as a prevention option: “Oftentimes I 
have to remind patients that the same way you become infected with chlamydia or 
gonorrhea [is the same way you become infected with HIV], and I think that that is a 
shock factor for a number of patients in terms of, what do you mean? What do you mean I 
can actually get HIV this way?” (P-507). HIV-related stigma appeared to prevent 
patients from engaging in conversations about PrEP: “I feel like [patients] are scared 
when they hear that word [HIV]; they don’t even really want to take any steps or 
initiative to protecting their health” (S-505). Additionally, unlike birth control which can 
offer multiple benefits, PrEP has one benefit. This distinction, particularly for women 
who may have low perceived risk or infrequent high-risk behaviors, made it difficult for 
staff to explain how PrEP could fit into a patient’s life. Staff discussed the need to 
address these potential barriers, including the burden of PrEP care that patients must 
manage, in PrEP implementation: “We need to realize and adjust for patients, that they 
have lives, that are busy, and that might have monetary constraints, and how do we then 
provide PrEP services to individuals who coming back to the health center every three 
months for continued lab work is a potential barrier?” (S-501).  
5) Managing different and changing priorities across departments (context). The 
health promotion and clinical departments were primarily involved in the initiative’s 
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implementation. Collaboration could be difficult because of competing priorities between 
the departments: “We’re on different priority and timelines, which is inevitable, and it 
doesn’t always align” (S-503). A staff member described that the burden of 
implementation was sometimes placed more heavily on one department over another: “It 
has been a difficult dance between [departments]… it is not always an equal balance” 
(S-501). Further, health promotion staff members reported that they had to respond to 
external events, such as changing federal policies and a turbulent political landscape, due 
to the clinic’s role as an advocate for women’s health. These factors pulled focus from 
the initiative: “Our to-do list is always shifting because of how policies are popping up 
every day” (S-506). Staff reported that, at times, other issues needed to be prioritized 
over the initiative: “There is advocacy work that needs to be done. That is an urgent, in 
the moment need, so my attention and my investment needs to shift” (S-503).  
4.2.2 Themes related to implementation facilitators 
Despite these barriers, staff also identified several implementation facilitators. 
Five major themes emerged from the analysis related to implementation facilitators. 
Grouped by the corresponding i-PARIHS constructs, these themes were: 1) program fit 
within the organization’s goals and activities (innovation); 2) diversity of resources 
developed for the initiative (innovation); 3) staff and leadership support for PrEP services 
(recipients); 4) having a network of affiliates from which to draw resources (context); and 
5) relationships with the local community (context).  
1) Program fit within organization’s goals and activities (innovation). Staff described 
PrEP as fitting well with the clinic’s mission: “[The initiative] is directly aligned with 
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[our clinic]. We have a mission to serve women…with comprehensive reproductive and 
sexual health information and services” (S-501). On the health promotion side, staff 
discussed that they were able to integrate PrEP education into their previously established 
programming, such as their sexual health curriculum: “We’ve done a good job of 
integrating PrEP into everything we do, it’s pretty much in all of our educational 
offerings” (S-506). A staff member described that incorporating PrEP across clinical and 
health promotion services oriented the clinic back to its “pillars” of health care and health 
promotion: “The PrEP initiative has been very helpful and has been a great facilitator of 
centering us on the linkage to care. So that when we are out in the community… there is 
always the follow-up of, you can find these services at [site A]” (S-501). From the 
clinical services perspective, adding PrEP made sense as patients sought similar sexual 
and reproductive health services at the clinic: “I think in particular because of the nature 
of testing for STIs, and because we’re so focused on reproductive health, I think that we 
have the opportunity to capture women who are at risk [for HIV]” (P-502).  
2) Diversity of PrEP resources developed for the initiative (innovation). Participants 
reported that the diversity of resources they created supported their efforts to provide 
PrEP information to women both in the clinic and in outreach settings. In the clinic, a 
binder created by the clinic lead assisted providers: “Having a binder full of algorithms, 
and charts, and [frequently asked questions], and common concerns, and all that 
different stuff… each patient receives the same amount of evidence-based patient-
centered care. I think having those resources available have really helped tremendously” 
(P-507). Health promotion staff described materials used during outreach, such as printed 
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educational materials and various “swag” (e.g., PrEP-branded stickers, condoms), as 
helpful for engaging women: “If someone is walking by, I may hand them a condom 
booklet and I also bring candy, because even adults respond well to getting candy…. And 
I get them to come over to the table, and I give them more materials, and they ask me 
questions” (S-506).  
3) Staff and leadership support for PrEP services (recipients). Staff reported 
leadership support as a critical factor for implementation. This support paved the way for 
the clinic to incorporate PrEP: “I think the first [facilitator] is the guidance and 
leadership of senior management around PrEP is really important” (S-501). Another 
staff member perceived that the initiative was a “pretty high priority” (S-503) for 
leadership. A provider echoed this sentiment: “From the administrative component, 
we’ve had support from higher up in the administration for bringing it on board” (P-
502).  
Staff also voiced their own support for providing PrEP, describing PrEP as a 
critical HIV prevention tool for women: “I don’t think we’ve seen anything that can be so 
impactful as PrEP in a long time for women and for communities affected by HIV” (S-
501). Similarly, a provider described why PrEP could be particularly meaningful in 
Washington, DC, stating, “I think it can have a really positive impact on our patients 
considering we are here in DC where there is the highest HIV population in the country” 
(P-508). Staff also described PrEP as an enabling tool for women: “This is such a 
liberating medication… this is another way [women] can feel empowered to protect 
themselves” (S-503). 
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4) Network of affiliates from which to draw resources (context). Though site A was 
the only affiliate within their network to have a PrEP program specifically for women, 
staff cited that they were able to learn from their other affiliates’ experiences with PrEP 
delivery to men who have sex with men (MSM). A health promotion staff member 
explained, “Being able to collaborate with other affiliates and learn from other people’s 
challenges, and share challenges and successes, and learn from each other - I think it’s 
been really great to see how generous folks have been and how mission-oriented folks 
have been” (S-503). Staff described that they adapted affiliates’ resources, including 
PrEP promotional materials and clinical protocols: “Our affiliates have a number of 
PrEP documents that are pretty standardized that offer a lot of information about what 
PrEP is” (P-507).  
5) Relationships with the local community (context). Participants discussed that 
relationships within the local community, including with the other PWI sites, were 
helpful for implementation. Participants cited that established relationships with external 
organizations (e.g., DC Department of Health, DC Public Schools), community members, 
and staff’s own knowledge of the broader community led to outreach opportunities: “A 
lot of the health educators are very well connected in the community, and people come up 
to them with events...[it’s] a mix of people coming to us and knowing what kind of events 
are going on in the community” (S-503). Staff also described the collaboration with the 
other PWI sites as supporting implementation: “I have already utilized those 
relationships to help with answering questions about best practices. I relied on our 
partners…having strong partners has been helpful” (S-506).  
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4.3 Site B case study 
Site B is a pediatric hospital that has operated in Washington, DC for over one 
hundred years. Since 2015, Site B has operated a universal, opt-out HIV and STI point-
of-care testing program through their community-based pediatric ED. Unlike sites A and 
C which focused on PrEP provision to adult WOC, Site B focused on PrEP provision to 
young women of color (YWOC) aged 13-24. Previously, site B had not prescribed PrEP 
to any YWOC. The PrEP Coordinator37, who oversaw the PrEP activities at the ED, was 
to provide PrEP counseling to YWOC who screened positive for a STI. Site B established 
the following four goals for their first year of PrEP implementation: 1) 20 ED providers 
will be trained in PrEP prescribing38; 2) staff and providers will provide PrEP 
information to 400 YWOC; 3) providers will prescribe PrEP to 22 YWOC; and 4) the 
PrEP Coordinator, in collaboration with an ID provider with expertise in PrEP, will build 
the capacity of 25 external primary care providers (PCPs) to prescribe PrEP to YWOC.39 
Site B reached goals 1 and 2, training 39 ED providers and providing PrEP information to 
694 YWOC. Site B did not meet goals 3 and 4; by the end of the first year, providers had 
not prescribed PrEP to any YWOC and no external PCPs were trained in PrEP. I 
conducted seven interviews at baseline. Due to staff turnover and availability, only five 
individuals were able to participate again in follow-up interviews. All participants except 
                                               
37The PrEP Coordinator was part of the health promotion staff and not a licensed independent 
practitioner. Therefore, the PrEP Coordinator could not prescribe PrEP.  
38 The PrEP Coordinator trained health promotion staff and clinical support staff in PrEP counseling. 
An ID specialist with expertise in PrEP trained providers in PrEP counseling and prescribing, 
supported by the PrEP Coordinator. 
39 See Appendix E, Supplemental Tables 11 and 12 for a brief description and corresponding timeline 
for these components. 
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one were female. Participants included two health promotion staff, two clinical support 
staff, and three providers. 
4.3.1 Themes related to implementation barriers 
Five major themes emerged from analysis of implementation barriers. Grouped by 
corresponding i-PARIHS constructs, these themes were: 1) resistance to prescribing PrEP 
(innovation); 2) staff and provider time limitations (recipients); 3) concerns about 
protecting patients’ confidentiality (recipients); 4) staff and provider perception of 
patient-level barriers that needed to be addressed in implementation (recipients); and 5) 
lack of engagement from external providers (context). Each theme is described below.  
1) Resistance to prescribing PrEP (innovation). Staff and providers expressed 
resistance to prescribing PrEP in the ED because they were concerned that patients would 
not receive appropriate long-term PrEP care. A provider explained how she felt a 
responsibility to ensure a patient prescribed PrEP was receiving care after the patient left 
the ED: “Because prescribing [PrEP] is not like prescribing Plan B, right, prescribing 
Plan B is like one medication order and we’re done. [PrEP] is a whole separate 
situation…. There needs to be some follow up on the ED end as well” (P-303). A staff 
member agreed, voicing worry that patients would not follow up with their primary care 
doctor: “If we are starting them on the PrEP, then making sure that they have adequate 
follow up could be a barrier. Because we can start it but we can only give you but so 
much before you need to go to your doctor” (S-307). Some providers voiced that long-
term medication such as PrEP should only be prescribed by a PCP, with one provider 
stating, “I’m not going to start prescribing a medication to treat you for long term, that’s 
  71 
something that a primary care doctor needs to follow you for and treat you for” (P-304). 
2) Staff and provider time limitations (recipients). Staff had limited time to discuss 
PrEP with patients as they needed to maintain the rapid flow of patients through the ED. 
Staff described that it was challenging to integrate PrEP counseling into the workflow, 
with one staff member explaining, “It has sort of been a bit of a trial period for our PrEP 
Coordinator seeing when and where the best time is to approach the patients to talk to 
them about PrEP” (S-301). Time with patients was already tight, which caused staff to 
miss potentially eligible patients during busy times: “[We] don’t always hit everyone 
[with PrEP information] because it’s been so busy” (S-306) and that “We barely get the 
universal STI screening done… more importantly getting them out the door becomes the 
most important thing” (P-305). Providers discussed that they had to use their limited time 
with patients to address patients’ chief complaints: “But if they come in for an ankle 
sprain, because I only have a certain amount of time to spend in the room with them, I 
won’t bring up that issue. I just don’t have time to kind of have a worthwhile discussion” 
(P-304). Another provider echoed this sentiment, stating, “We would need an extra team 
because like I said, the physicians don’t have time. But I think a community health 
educator, a MPH…could get that done” (P-305).  
3) Protecting patients’ confidentiality (recipients). Staff expressed concerns about 
maintaining the confidentiality of their patients under the age of 18 while delivering 
PrEP. This issue intersected with logistical barriers to maintaining confidentiality: 
“There’s also issues of adolescent confidentiality and if the patient is in a random room, 
then you have to take them down the hall. And if you can’t take them down the hall and 
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send their parent away, it’s a whole thing” (P-305). Ensuring confidentiality in the ED 
was uniquely challenging, as compared to a primary care setting. A provider explained, 
“It’s one thing when you have yourself together enough to go to a PCP appointment and 
the PCP can prepare the parent.... But when your 16-year-old goes to the ED for a 
sprained ankle, you do not see any of that coming” (P-304). Confidentiality concerns 
extended beyond the ED visit, such as parents finding out that their child was on PrEP 
from an insurance bill: “If this is a 16-year-old kid and they are here without mom, but 
then mom finds out that they’re on PrEP... how do we navigate it?” (S-301).  
4) Staff and provider perception of patient-level barriers that needed to be 
addressed in implementation (recipients). Staff perceived a number of potential patient-
level barriers to PrEP uptake that arose during their conversations with YWOC. Staff 
discussed the need to address these potential barriers in their PrEP implementation. Staff 
perceived limited patient knowledge about how HIV is transmitted; HIV-related stigma; 
PrEP as a low priority; and resistance from parents/guardians of minor-aged youth as 
potential barriers for YWOC. Staff described that it seemed many YWOC lacked a basic 
understanding of HIV transmission; therefore, it was necessary for staff to first provide 
HIV education before introducing PrEP. A provider explained, “We can’t assume that 
HIV knowledge is general knowledge. It’s not. I think that’s the hard part. So just 
understanding that there are so many levels to this before we start saying what PrEP is” 
(P-304). Staff remarked that it appeared patients did not want to discuss PrEP due to a 
perceived stigma associated with HIV: “So I feel like most of them don’t want to talk 
about that…. I think [HIV] is a huge issue with stigma around it” (S-307). Additionally, 
  73 
staff reported that it seemed a daily pill for HIV prevention may be a low priority for 
YWOC, compared to other, more urgent issues: “Because it’s like, you’re calling to tell 
me about a pill? And that’s the least of my worries right now. I need to worry about how 
I’m going to eat, how I’m going to make it to school…. That connection piece really 
needs to happen. And so for me, in my mind, we just need to continue to educate more” 
(S-302). Though staff reported that some YWOC visited the ED alone, when a 
parent/guardian did accompany their child, this could present a challenge: “Either [the 
parents/guardians] are not engaged in care, they don’t want me in the room, or they’re 
like, I’m being insensitive…. So the guardians have actually been my hardest group to 
tackle throughout this whole thing” (S-302).  
5) Lack of engagement from external providers (context).  Site B’s fourth goal was to 
build the capacity of PCPs in the local area to provide PrEP to YWOC. Health promotion 
staff described that external PCPs did not reply to their outreach attempts: “The 
physicians have not been responding whatsoever. Many of the offices were telling me that 
providers were not able to talk to me, or they would take my number and not call me 
back” (S-301). Staff perceived that external PCPs’ lack of engagement was related to the 
belief that they were not responsible for providing PrEP: “Most of them are wanting 
somebody else to kind of take care of it” (S-302). Similarly, a provider described that it 
appeared some PCPs viewed PrEP as outside of their purview: “I still find that in DC 
despite some good, positive strides and every [Medical Doctor] has to have three hours 
of [Continuing Education], et cetera, there is still kind of this attitude of, oh that’s in the 
domain of this doctor, that’s not something I need to be worrying about” (P-303).  
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4.3.2 Themes related to implementation facilitators 
Four major themes emerged from analysis of implementation facilitators. 
Grouped by corresponding i-PARIHS construct, these themes were: 1) having a 
centralized PrEP Coordinator (innovation); 2) staff and leadership support of PrEP 
provision (recipient); 3) building from the point-of-care testing program (context); and 4) 
the ED as an access point for health care for YWOC (context). 
1) Having a centralized PrEP Coordinator (innovation). Staff frequently cited the 
PrEP Coordinator as helpful to integrating PrEP into the ED. A provider explained, “We 
were very lucky to have a designated coordinator for the project…. The ongoing presence 
of the dedicated coordinator has made a huge difference for us” (P-303). The PrEP 
Coordinator removed the burden of implementation from other staff: “Having the [PrEP 
Coordinator] here, and here to spearhead for that initial phase, I think it helps because it 
keeps the nurses from having to do so much” (S-307). However, participants also 
recognized that having the PrEP Coordinator responsible for all PrEP activities could be 
unrealistic. One participant explained, “I guess having the [PrEP Coordinator] do it all 
for us [has been helpful]. But I know that’s not always feasible” (S-306).  
2) Staff and leadership support of PrEP provision (recipient). Participants reported 
that leadership from both the hospital and the ED backed the initiative: “[The initiative] 
was very much endorsed and picked up by the leadership in the ED…and the wider team 
at [the hospital]” (P-303). The ED leadership in particular was described as, “…very 
positive, very supportive about having programs like this available” (P-304).  
Participants expressed excitement toward providing another HIV prevention 
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option for YWOC in the ED: “I think that being able to expand the PrEP services, which 
have been primarily given to men who have sex with men, to women and specifically 
young women, I think it’s a really powerful tool” (S-301). Participants believed PrEP 
could have a positive impact on YWOC: “PrEP is one of those things that is simple and 
relatively high benefit, low risk to make them aware of and give them the option of having 
it, that if we are able to successfully implement it here, I think that will be a definite plus” 
(P-304).  
3) Building from the point-of-care testing program (context). The established point-of-
care testing program was described as a supportive factor for PrEP implementation. This 
program put in place processes that facilitated PrEP provision, such as identifying 
patients who came in for STI screening on a tracking board: “If any patient identifies 
with any STI concerns, whether it is exposure, they want to get tested, they are coming in 
specifically requesting any form of STI testing, that will go on the tracking board which 
would then be alerting me to go in and speak directly with that patient” (S-302). The 
testing program also created an alert in the EMR that notified staff of a patient’s potential 
PrEP eligibility (i.e., positive STI screening): “We launched a PowerForm for our HIV 
and STI screening, so now it’s built into our electronic medical records…which is 
helping us identify some of the young women who are at risk [of HIV infection]” (S-301). 
Additionally, staff received monthly progress reports on the testing program, including 
number of patients screened for STIs and number of patients who received treatment. 
This feedback demonstrated to staff that they could play a role in reaching young women 
at risk for HIV: “Because of this screening program that we are doing, [the patient] was 
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identified as having a STI and treated. [We] really get to see the benefit of what [we] are 
doing” (S-306).  
4) The ED as an access point for health care for high-risk YWOC (context). 
Participants described that offering PrEP through the ED made sense as many YWOC 
received care through the ED. A provider perceived that some YWOC utilized the ED 
more frequently than primary care: “I get the sense that a lot of the health care needs that 
they have get addressed through the ED as opposed to through their primary care doctor. 
So the benefit of running PrEP through the ED is that you are reaching the target 
population where they are interfacing with the health care community” (P-304). 
Participants reported that some YWOC who utilized the ED for sexual health care built 
relationships with ED staff: “We have lots of patients who come in and they have regular 
HIV and STI screens, more than once a year, and kind of have a good rapport with some 
of the staff” (S-301). Another provider described that the young women who came into 
the ED were the target population for the initiative, i.e., YWOC at risk for HIV 
transmission: “But I think [PrEP] will be only beneficial because we see a fairly high-
risk population here…. There are plenty of women that are high risk and I think they can 
only benefit from [PrEP]” (P-305). 
4.4 Site C case study 
Site C is a Federally Qualified Health Center (FQHC) comprised of five primary 
care clinics in Washington, DC. Site C, like site A, focused on PrEP provision to adult 
WOC. A PrEP Coordinator oversaw PrEP activities.40 Site C had previously prescribed 
                                               
40As at site B, the PrEP Coordinator at site C was a clinical support staff member, and not a licensed 
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PrEP, but not to any WOC. Site C established the following three goals for their first year 
of PrEP implementation: 1) 130 health promotion staff, clinical support staff, and 
providers will be trained in PrEP41; 2) clinical support staff and providers will provide 
PrEP information to 5,000 WOC either through direct outreach in the community or 
during appointments in the clinics; and 3) providers will prescribe PrEP to 125 WOC. 42 
Site C met goal 1, training 188 staff (including 61 providers) in PrEP. However, the site 
did not reach goals 2 and 3. By the end of the first year of PrEP delivery, 1,614 
individuals43 received PrEP information and providers prescribed PrEP to only three 
WOC. I conducted a total of nine interviews, with five participants at baseline and four 
participants at follow-up. Due to staff turnover and availability, only one individual was 
interviewed at both baseline and follow-up. Six participants were female and two 
participants were male. Participants included three clinical support staff and five 
providers. 
4.4.1 Themes related to implementation barriers 
Five major themes emerged from the analysis related to implementation barriers. 
Grouped by corresponding i-PARIHS constructs, these themes were: 1) differences in 
approach to screening for PrEP eligibility among providers (innovation); 2) provider time 
limitations (recipients); 3) staff and provider perception of patient-level barriers that 
                                               
independent practitioner. Therefore, the PrEP Coordinator could not prescribe PrEP. 
41The PrEP Coordinator trained health promotion staff and clinical support staff in PrEP counseling. 
An ID specialist with experience in PrEP prescribing trained providers in PrEP counseling and 
prescribing, supported by the PrEP Coordinator. 
42See Appendix E, Supplemental Tables 13 and 14 for a brief description and corresponding timeline 
for these components. 
43 Site C did not report demographic data for individuals who received PrEP information, therefore it 
is unknown how many of these individuals were WOC.  
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needed to be addressed in implementation (recipients); 4) limitations of the electronic 
medical record (context); and 5) navigating the complex insurance landscape (context). 
Each theme is described below. Illustrative quotes are presented with participant role (P 
for provider, S for staff member) and participant identification number. 
1) Differences in approach to screening for PrEP eligibility among providers 
(innovation). Despite the institution of a two-step PrEP screening protocol in which 
providers screened patients for PrEP eligibility using a sexual health history screener and 
then referred patients to the PrEP Coordinator or other clinical support staff, providers’ 
approaches to the PrEP protocol differed. Some providers followed the protocol closely 
and initiated sexual health conversations with their patients in order to assess risk factors 
for HIV: “It is primarily conversations during the taking of the sexual health history and 
social history questionnaire, and explaining what the benefits of PrEP and also the 
commitment that is PrEP and seeing if that is something they are interested in” (P-106). 
Other providers did not probe about risk factors but rather waited for patients to identify 
their own risk factors. Despite being trained in PrEP screening, one provider was 
unaware that a standardized protocol was in place, stating, “We just need to protocolize 
when we have that conversation to ensure that we are doing it for everybody. Because 
right now, “I don’t routinely screen every single patient I see, I use identifiable risk 
factors that come to my attention…. I think that I’m missing a significant portion of 
people who are eligible” (P-103). Some staff stated that they did not know if providers 
were speaking with their patients about PrEP, with one clinical support staff member 
stating, “It’s all dependent on the providers how the process goes” (S-101), while a 
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provider wondered, “I don’t know how many of my colleagues do that. That is something 
that I am particularly interested in” (P-105).  
2) Provider time limitations (recipients). Discussing PrEP during a patient’s visit was 
challenging for providers due to the limited time available at each visit. Providers 
explained that integrating PrEP into an already full patient visit was difficult: “It is hard 
to find time. If there is somebody who has multiple chronic diseases, and they’re there for 
their physical, and I also have to talk to them about their diet and exercise….” (P-105). 
Another provider expressed that it was not feasible for providers to screen all patients for 
PrEP eligibility: “So we have to consider all of these things and how we’re going to use 
that 15-minute visit for a physical, which is insane, you know what I mean? … I think that 
realistically there is no way that all of the providers are going to be focusing, are going 
to be offering PrEP to all those women and men who are eligible” (P-103). If a patient 
was interested in PrEP, providers would have the patient schedule another appointment as 
there was not enough time in one visit to thoroughly discuss PrEP: “Of course I don’t 
have a ton of time in one of those appointments to just talk about PrEP. Usually I say, 
let’s do some labs and bring you back to talk about that part if you’re interested” (P-
108). This second appointment would typically be with the PrEP Coordinator for further 
counseling on PrEP.  
3) Staff and provider perception of patient-level barriers that needed to be 
addressed in implementation (recipients). Staff perceived a number of potential patient-
level barriers to PrEP uptake that arose during their conversations with WOC. Staff 
perceived concerns about how to pay for PrEP, stigma related to “risky” sexual 
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behaviors, and women’s low perceived risk of HIV infection as potential barriers for 
patients. Staff reported that some patients appeared worried that their insurance would 
not cover PrEP: “[I get] a lot of financial questions, if it’s going to get covered by 
insurance, if not, how will I be able to pay for it” (S-102). Staff also described patients as 
hesitant to initiate PrEP due to the stigma associated with being labeled as someone who 
engages in risky behaviors. A provider described a patient refraining from PrEP out of 
fear of being assigned the diagnostic code for “high risk sexual behavior” in her medical 
record: “And that is when it turned around from, yeah I’m going to do this, to no, I’m not 
that person. I’m not a high-risk person” (P-105). Staff also reported that it appeared 
female patients had a low perceived risk of HIV infection, which held patients back from 
engaging in conversations about HIV prevention: “I don’t think women see [HIV] as an 
issue for them to concern themselves with” (S-101). Another staff member remarked that 
she learned that providing education on HIV transmission helped her patients better 
understand HIV risk factors: “I think when it comes to talking to at risk women, a lot of 
times I feel women have talked about sexuality, about sexual health and all, that there is 
this assumption that they trust their partners and they minimize the risk involved. So that 
has been a learning experience for me… just doing a little more education, I guess” (S-
102).   
4) Limitations of the electronic medical record (context). Limitations in the EMR 
system made it difficult to document PrEP-related conversations with patients. For 
example, the EMR did not contain a template for the sexual health history screener used 
to assess PrEP eligibility in which providers could input patient notes. A provider 
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described how patient notes were recorded: “We don’t really use a clinic-based template 
for physicals and stuff, everybody uses their own… it has been rather piecemeal at this 
point” (P-103). If a patient was referred to the PrEP Coordinator, the Coordinator had to 
search through the EMR to find details about the provider and patient’s previous 
conversation, as there was no designated form or location in the EMR in which this 
information was entered. A staff member remarked on this process: “We’d have to 
convert [the notes] over, so it’s not as easy … you may not really see the details of the 
discussion or the conversation” (S-102). In addition, it was not possible to extract data 
needed to monitor the initiative: “We don’t really have a good way of capturing 
information… it makes it a little challenging to capture what we actually do” (S-101).  
5) Navigating the complex insurance landscape (context). Dealing with insurance 
companies to obtain prior authorization affected patients’ care. One provider explained, 
“Because of the health care landscape that I practice in, [PrEP] is something that 
requires prior authorization often times, so there is a little bit of a delay” (P-106). 
Enrollment in drug payment assistance programs often required an extra clinic visit to 
complete paperwork, and coverage could be temporary. A staff member described one 
patient’s experience: “We just learned today about a patient who when they were 
approved, they were only approved for 180 days and they have to reapply” (S-101). 
Though US citizenship is not a requirement for these programs, for patients with 
undocumented citizenship status, enrollment into these programs raised concerns about 
their citizenship status being revealed. As one staff member questioned, “What do we do 
with someone that is undocumented and does not have insurance and wants to access it. 
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What do we do about that?” (S-104). To address this barrier, a provider remarked that 
having a point person on staff for insurance issues would be beneficial: “I think that an 
insurance navigator or someone who is aware of different assistance programs and ways 
to get the medicine to patients would be really helpful” (P-107).  
4.4.2 Themes related to implementation facilitators 
 Despite these barriers, staff also identified several implementation facilitators. 
Five major themes emerged from analysis related to implementation facilitators. Grouped 
by the corresponding i-PARIHS constructs, these themes were: 1) program fit within 
organization’s goals and activities (innovation); 2) having a centralized PrEP coordinator 
(innovation); 3) staff and leadership support of PrEP provision (recipients); 4) PrEP as 
empowering women (recipients); and 5) relationships within the local community 
(context). Each theme is described below. 
1) Program fit within organization’s goals and activities (innovation). Staff described 
that the initiative was a good fit with the mission of the clinic as the clinic sought to 
provide comprehensive HIV prevention services to their patients, with a focus on serving 
immigrants in the DC region. A staff member explained, “Historically [site C] started 
for immigrants, and immigrant women, and providing health to women so it has certainly 
been a part of what [we] do, so it is a good fit” (S-101). Another staff member remarked 
that offering HIV prevention options was important due to the HIV burden in the 
immigrant population: “…there have been some advances on [HIV] transmissions, on 
slowing down transmissions. But within immigrant communities, that is not the case, so 
that influenced the organization to get more involved and to take upon this type of 
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program within the organization” (S-102). Staff viewed PrEP as a natural extension of 
the clinic’s services for women and an opportunity to provide another HIV prevention 
option to their clients: “I think [this initiative] is ideal… I think it’s something that 
definitely was missing” (S-104).  
2) Having a centralized PrEP coordinator (innovation). Having a centralized PrEP 
coordinator was a supportive factor for implementation. One staff member described the 
PrEP Coordinator as “…the information central so that we know where to go instead of 
just wondering who should we contact” (S-102). Providers explained that they would 
seek the PrEP Coordinator’s advice when considering prescribing PrEP to patients: “I 
would just call him and say, hey this is a specific situation, what do you think, should they 
follow up sooner, things like that. It’s been good to have a role like that” (P-108). The 
PrEP Coordinator was able to provide critical care coordination for PrEP patients that 
would not be available otherwise. A provider explained the importance of this role as, 
“Because that level of the coordination of care, I don’t think our system, without having 
somebody there to do that support, it is much harder…. So having [the PrEP 
Coordinator] there is key” (P-105).  
3) Staff and leadership support of PrEP provision (recipients). Leadership investment 
in the initiative supported implementation. A provider described how leadership 
supported staff training by “facilitating the education component and making it a 
requirement for the clinical team” (P-103). Staff described that leadership was taking 
steps to support the initiative, with one staff member stating, “I believe the organization 
is investing in it, providing all the tools, all the information that we need, how to provide 
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care for the patient and support for the providers” (S-102).  
In addition to leadership support, participants voiced their own support for the 
initiative. A provider described that he was motivated to discuss PrEP because he 
believed it would positively affect his patients’ health, “…if we take five minutes to talk 
about PrEP, we have a very measurable and profound impact on risk reduction” (P-
103). Another provider commented that, overall, staff and providers were invested in the 
initiative: “Providers are engaged, and the clinic as a whole is engaged to learn and to 
offer PrEP. I think that’s the biggest piece, that we have a supportive environment that is 
willing to learn and engage clients with regards to the topic” (P-101).  
4) PrEP as empowering women (recipients). Staff were motivated to provide PrEP as 
they viewed it as empowering women. A staff member explained her support for PrEP as, 
“For me, it’s the result. I think knowing that for a moment someone made a choice for 
themselves, because it’s all a matter of taking power for oneself, you know you’re 
empowering yourself.... That makes me extremely excited” (S-104). Another staff 
member commented that even if the initiative did not lead to PrEP uptake, providing 
women with PrEP information would still be powerful: “So if the program doesn’t do 
anything, if it at least empowers them in that regard, then we’ve done a good thing” (P-
105). Staff discussed how a women-controlled method for HIV prevention empowered 
women: “…it’s about how we can empower women to know that they have another 
option. Similar to the female condom, empowering women with regards to things that 
they have in their toolkit or purse to support protecting themselves” (S-101).  
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5) Relationships within the local community (context). The clinic’s relationships 
within the community, including the other PrEP for Women Initiative sites, supported 
PrEP implementation. Staff described relationships with other PWI sites as helpful. In 
addition to partnering with sites on outreach events, sites had monthly calls where 
partners discussed their efforts. One participant reported that monthly calls among the 
sites were, “opportunities to share expertise with a team who are engaged and receptive 
to ideas” (S-102). Another staff member described strategizing with other sites about 
implementation activities, including, “… how it is that we want to move forward, how it 
is that we are going care for the patients, and so on” (S-104). Additionally, one 
participant taught sexual and reproductive health care to nursing students at a local 
historically Black university. These students had the option to receive PrEP training and 
participate in PrEP outreach. The participant described how this relationship was 
leveraged: “They become like ambassadors if you will, where they can go and now talk to 
other young women their age about PrEP and their options” (S-101).  
4.5 Chapter summary 
Across the initiative, sites exceeded their goal of 212 staff and providers trained in 
PrEP, with 289 staff and providers being trained in PrEP. Sites had expected to provide 
PrEP information (either through direct outreach or in clinic) or PrEP counseling to 7,900 
WOC; however, sites fell short, reaching 6,686 WOC. Finally, though sites had 
anticipated prescribing PrEP to 387 WOC, by the end of the year, only providers at site C 
had prescribed PrEP, and only to three WOC. Participants reported several key themes 
related to implementation barriers and facilitators, outlined in Table 9, below. Three 
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themes overlapped across all three sites. First, participants from all sites reported time 
limitations as a challenge to PrEP implementation. Staff and providers reported this 
challenge at sites A and B, but at site C, only providers reported this challenge. Second, 
participants from all sites reported perceiving a number of patient-level barriers that they 
felt needed to be addressed in implementation. For example, at site B, participants 
discussed that they needed to start PrEP conversations with a basic overview of how HIV 
and STIs are transmitted before launching into PrEP counseling. Participants appeared 
surprised by the level of patient education needed about HIV and STI transmission prior 
to discussing PrEP. Third, participants at all sites reported that staff and leadership of 
PrEP provision was a supportive factor for PrEP implementation. Yet, despite the support 
for PrEP, along with other facilitative factors, providers identified a number of 
implementation barriers. The following chapter discusses these findings and makes 
practice recommendations to support and improve PrEP implementation for WOC.   
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Table 9. Implementation barriers and facilitators, organized by the i-PARIHS constructs of innovation, recipients, and context 
  Barriers Site A 
Site 
B 
Site 
C Facilitators 
Site 
A 
Site 
B 
Site 
C 
Innovation 
(degree of fit, 
compatibility, 
diffusion) 
Differences in understanding of the PrEP 
protocol among staff and providers ■   
Program fit within the organization’s 
goals and activities ■  ■ 
Resistance to prescribing PrEP  ■  Diversity of resources developed for the initiative ■   
Differences in approach to screening for 
PrEP eligibility among providers   ■ 
Having a centralized PrEP 
Coordinator  ■ ■ 
Recipients 
(capacity, 
attitudes, 
beliefs, skills) 
Staff and provider time limitations* ■ ■ ■ Staff and leadership support for PrEP services ■ ■ ■ 
Staff discomfort providing PrEP 
counseling ■   PrEP as empowering women   ■ 
Staff and provider perception of patient-
level barriers that needed to be 
addressed in implementation 
■ ■ ■ 
 
Protecting patients’ confidentiality  ■  
Context 
(organizational 
priorities, 
relationships) 
Managing different and changing 
priorities across departments ■   
Having a network of affiliates from 
which to draw resources ■   
Lack of engagement from external 
providers  ■  
Relationships with the local 
community ■  ■ 
Limitations of the electronic medical 
record   ■ 
Building from the point-of-care-
testing program  ■  
Navigating the complex insurance 
landscape   ■ 
The ED as an access point for health 
care for YWOC  ■  
■ Indicates theme was identified by site 
* For site C, time limitation was identified as a barrier for providers only 
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
5.1 Chapter overview 
Guided by the i-PARIHS implementation science framework, this study explored 
perspective of clinic staff and providers at three clinical sites on factors that affected 
PrEP implementation for WOC. In this chapter, I consider the key themes related to 
implementation barriers and facilitators across study sites as identified in Chapter 4, and 
provide recommendations to support PrEP implementation for WOC (Table 10, end of 
chapter). I also discuss policy and research recommendations drawn from the findings, 
the utility of the i-PARIHS framework, and the study’s limitations.    
5.2 Discussion and practice recommendations 
Although the three sites met their program goals regarding numbers of staff 
trained and WOC reached with PrEP information, these efforts did not result in 
prescribing PrEP to WOC. Only providers at one site prescribed PrEP, and only to three 
WOC. The i-PARIHS framework posits that meeting program goals, embedding PrEP 
into practice, and staff and providers’ investment in PrEP are characteristics of successful 
implementation (45). PrEP was not embedded into practice, with participants citing 
factors such as time limitations and lack of clarity or different approaches to key 
components of implementation as implementation barriers. Although participants 
described staff and leadership as supportive of PrEP (e.g., leadership required PrEP 
training; staff viewed PrEP as a potentially impactful HIV prevention method for women) 
and PrEP as a good fit within their organizations (e.g., providing PrEP was consistent 
with their organization’s mission), there was a lack of ownership of PrEP. Staff reported 
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various reasons for not speaking with patients about PrEP, including concerns about 
linking patients to long-term care, discomfort providing PrEP counseling, and staff 
perceptions that patients were faced with significant barriers that staff were not able to 
address (e.g., cost of PrEP).  
In the i-PARIHS framework, facilitation is a process that enables implementation 
(44,45). The recommendations identified here focus on improving the facilitation of PrEP 
implementation by addressing factors that support or hinder recipients’ (staff and 
providers’) uptake of the innovation (PrEP) within the specific context (the clinic and 
wider health system). Through the analysis of in-depth interviews that probed participants 
on factors related to the i-PARIHS constructs of recipients, innovation, context, and 
facilitation, and informed by the literature review presented in Chapter 2, I identified 
three overarching practice recommendations for successful PrEP implementation for 
WOC: 1) clarify staff roles and responsibilities; 2) engage staff through ongoing feedback 
and targeted training; and 3) ensure care is focused on WOC’s needs and experiences. 
Each practice recommendations contains specific strategies that address implementation 
barriers and facilitators identified through this research. I also identify the i-PARIHS 
construct(s) addressed by each recommendation.   
Practice recommendation 1: Clarify staff roles and responsibilities. 
 
Strategy #1: Site leadership should specify a PrEP coordinator (or PrEP coordinators) 
to facilitate implementation. Construct addressed: facilitation  
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Participants from the two sites with a PrEP coordinator described the coordinator 
as supportive of and a critical resource for PrEP implementation. At the site without a 
PrEP coordinator, various staff led different aspects of implementation, with department 
heads serving as de facto implementation leaders.44 Across sites, facilitation was not 
viewed as a process with ongoing assessment of how the staff and providers were 
understanding and implementing PrEP. Rather, facilitation was a series of task-focused 
activities (e.g., training sessions) with information delivered to staff and providers. As 
facilitators, effective PrEP coordinators should be able to explain and demonstrate the 
task, as well as diagnose challenges and adapt implementation as needed (45,164,165). 
For example, as a registered nurse, the PrEP Coordinator at site C was able to discuss the 
clinical aspects of PrEP with staff, providers, and patients, and was familiar with the 
systems (e.g., EMR) and processes of the clinic. For PrEP programs that span across 
departments (e.g., health promotion and clinical support), a coordinator from each 
department is helpful to harmonize efforts and balance priorities across departments. 
Appointing a coordinator to facilitate implementation has been useful with similar 
innovations (e.g., family planning, HIV testing) (147,152,166). Designating a PrEP 
coordinator (or coordination team) assigns the responsibility for leading implementation. 
                                               
44 Site A intended to have a PrEP coordinator from the beginning of the initiative, but due to hiring 
delays and staff turnover, the PrEP coordinator was not hired until the end of the third quarter. 
Strategy #2: Prior to implementation, the PrEP coordinator(s) should clearly specify 
staff roles, responsibilities, and opportunities to engage women. Constructs addressed: 
innovation, recipients, context 
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Participants reported discrepancies in their understanding of the PrEP protocol 
and approach to PrEP screening. For example, at one site, while both clinical support 
staff and providers were supposed to conduct PrEP screening, participants reported that 
the clinical support staff were not assessing patients for PrEP eligibility. At another site, 
some participants were unaware that a sexual health history template was to be used for 
PrEP screening purposes. To successfully incorporate PrEP, clinics must be able to define 
the process by which staff and providers inform patients about PrEP and know who is 
responsible. Identifying the process, from the time patients enter the clinic through 
follow-up, sets a standard procedure for how PrEP information gets to women. Uptake of 
an innovation is more likely if the innovation is standardized into practice (45). Role 
clarity, particularly in an ED context, is important as there are many staff involved who 
may work different shifts (151,167). While staff expressed a willingness to participate, 
delineating appropriate roles will help translate willingness into action.  
 
Participants at every site reported time limitations as a challenge to 
integrating PrEP into patient visits. Providers felt that they did not have enough 
time during patient visits to screen for PrEP, particularly when there were other 
chronic conditions to be managed. Providers, including those in ED settings, have 
frequently reported limited time as a barrier to the adoption of a new innovation 
Strategy #3: The PrEP coordinator(s) should identify opportunities to shift the 
responsibility of PrEP counseling from providers to lay staff. Construct addressed: 
recipients 
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(92,103,110,113,151,167–172). One strategy to alleviate this burden would be to 
shift the task or responsibility of PrEP counseling from clinical providers to 
trained lay staff (e.g., case managers, counselors, peer educators). Clinics have 
successfully initiated patients onto PrEP by training lay staff to conduct client-
centered PrEP counseling (67,173). Such “task-shifting” has also been utilized 
successfully for ART initiation and retention, with a 2010 systematic review 
finding that shifting responsibility for ART initiation and monitoring from 
providers to lay staff resulted in high-quality, cost-effective care to more patients 
(174). Delegating the responsibility of PrEP counseling from providers to trained 
lay staff coupled with better defined staff roles and responsibilities, could address 
the challenge of limited time. 
Practice recommendation  2: Engage staff through ongoing feedback and 
targeted training 
 
Though staff and providers were supportive of adding PrEP as a service, their 
support did not necessarily result in PrEP prescribing, similar to findings from other PrEP 
studies (99,103,118). Providers may act as PrEP “gatekeepers,” holding PrEP knowledge 
of which women may not be aware, and have a responsibility to introduce PrEP to 
women in a way that does not stigmatize behavior (80,175). Previous research and 
Strategy #4: The PrEP coordinator(s) should incorporate targeted and ongoing booster 
training sessions and check-ins that include providing updated data on the program’s 
progress. Construct addressed: recipients 
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findings from this study show that staff and providers desire more training in PrEP to 
increase their comfort in PrEP counseling and prescribing (176). At the New York City 
Department of Mental Health and Hygiene, trained staff conducted brief, one-on-one 
training sessions with providers and clinic staff (177). These sessions, targeted to each 
staff member’s role, resulted in significant improvements in providers’ PrEP knowledge, 
and PrEP screening, and prescribing (177). The PrEP coordinator(s) should incorporate 
similarly targeted training for staff and providers involved in PrEP implementation. 
These trainings should also provide staff with updates on the clinic’s progress towards its 
program goals (e.g., number of WOC prescribed PrEP). Participants at site B reported 
that being informed about the progress of their site’s point-of-care HIV screening 
program through the sharing of routine administrative data (e.g., the number of HIV 
screenings that resulted in ART initiation) increased their investment in the program. By 
demonstrating to staff how their efforts provide excellent care to patients, the PrEP 
coordinator(s) can build staff investment in PrEP. 
 
As staff and providers become more comfortable in PrEP counseling and 
prescribing, the PrEP coordinator(s) can hold up the early adopters as “PrEP champions” 
to lead by example and assist in informal or formal training of their colleagues. 
Champions are staff or providers that voluntarily take the lead in helping with the 
Strategy #5: The PrEP coordinator(s) should identify and showcase those staff who 
adopt PrEP as champions, as well as consult with these staff to improve PrEP 
implementation. Construct addressed: recipients 
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implementation of something new in a setting (147). For example, as site C was the only 
site with providers that prescribed PrEP to WOC, these providers could be identified as 
PrEP champions. The PrEP coordinator(s) can showcase and discuss the champions’ 
successes (e.g., successfully initiating WOC onto PrEP, retaining WOC on PrEP) in 
trainings to motivate other staff. Champions can also serve as points of contact for other 
staff as questions or challenges arise, and as a liaison between staff and the PrEP 
coordinator(s) (147,175). These champions can assist in assessing the current process and 
developing an updated plan (147). This approach has been useful for delivery of similar 
services (e.g., family planning, HIV testing) (147,152,166).  
Practice recommendation 3: Ensure care is focused on WOC’s needs and 
experiences 
 
Participants in this study reported using different criteria to assess PrEP 
eligibility. The limited research on female PrEP patients has found that most were 
identified as PrEP candidates because they had a known HIV-infected sexual partner, 
suggesting that providers may not explore women’s risks beyond this criterion (75,76). 
USPHS guidelines recommend PrEP for women who are at “substantial risk for HIV 
acquisition” but do not define substantial risk (63). Interpretation of guidelines may differ 
among providers, suggesting that providers are unclear about PrEP eligibility criteria, and 
overlook women who are reluctant to disclose or do not know their risk factors 
(64,93,178,179). Indeed, a recent study demonstrated that the use of USPHS’ updated  
Strategy #6: PrEP should be integrated into routine, sexual, and reproductive health 
care visits for all women. Constructs addressed: innovation, recipients 
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guidelines to screen women overlooked many women with elevated HIV risk (64). A 
2019 study that retrospectively applied the updated guidelines to a sample of Southern 
women (83% Black) who are now HIV positive, found that a majority of the women 
would not be indicated for PrEP (180). Rather than categorizing women into discrete high 
risk groups using standardized screeners, recent literature recommends integrating PrEP 
education into routine, sexual, and reproductive health care for all women (80,81,181).  
Additionally, participants perceived several patient-level barriers to PrEP uptake 
that arose during conversations with patients, including the time and cost associated with 
quarterly medical appointments while on PrEP. In previous research, WOC have 
expressed concerns that being on PrEP may be burdensome for many reasons, including 
the cost and the number of office visits required, having to take a daily pill, and taking 
PrEP in addition to other medications, such as birth control (92,94). To address these 
concerns, clinics should make every effort to allow patients to initiate PrEP within one 
office visit, thereby saving patients both time and cost (e.g., patient would only have to 
find time and pay for one office visit instead of two). Kamis et al. (2019) found same-day 
PrEP initiation at a STI clinic in Denver, Colorado to be acceptable, feasible, and safe 
among a predominantly male population, with 78% of PrEP initiators completing at least 
one follow-up appointment (182). Mikati et al. (2019) also found same-day PrEP 
initiation at sexual health clinics in New York City to be safe (183).45 HIVE, a 
                                               
45 Women were significantly more likely to have delayed PrEP initiation compared to men (12% 
compared to 3%) due to findings from a medical evaluation (e.g., symptoms/signs of active HIV, 
history of kidney disease, or history of Hepatitis B infection) (183). However, all women who initiated 
PrEP were ultimately found to have no contraindication for PrEP (183). 
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reproductive and sexual health care organization based out of the University of California 
San Francisco, cites that family planning providers who were early adopters of PrEP 
found that bundling PrEP with other care was helpful in minimizing cost and time 
burdens (166,184). For example, family planning providers coupled PrEP initiation and 
monitoring visits with visits for injectable contraception or care for chronic conditions 
(166). Moving beyond standardized screeners and towards routinizing PrEP education for 
all women, as well as enabling PrEP initiation in one visit or combined with other care 
will better support access to PrEP for WOC (19,84,91–93). As clinics shift towards the 
routinization of PrEP and bundle PrEP with other care, consideration of how tasks can be 
shifted will be needed as to not overburden staff and providers.  
 
Staff described PrEP as an additional, potentially “empowering” HIV prevention 
option for women but believed that their patients faced significant barriers to initiating it, 
including stigma and fear. These factors are well-cited in the literature as factors that 
increase WOC’s vulnerability to HIV (8,9,81,181). Recent literature on PrEP counseling 
for women encourages the use of a shared decision-making approach to explore these 
vulnerabilities. The shared decision-making approach, frequently used in family 
planning, is a collaborative process in which clinicians offer multiple evidence-based 
options, patients explain their experiences and desires, and together the provider and 
patient create a plan (81,166,185). Shared decision-making allows for the exploration and 
Strategy #7: Staff and providers should be trained to take a shared decision-making 
approach to PrEP counseling. Constructs addressed: innovation, recipients 
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discussion of interpersonal, community, and structural-level barriers to care that are 
specific to WOC’s experiences (81,166,184). WOC who have engaged in this approach 
for contraception choices have reported higher satisfaction with their care than women 
who utilized a patient-only or provider-only approach (186). This approach could 
uncover factors that would not be seen through a risk assessment checklist, and clarify or 
correct staff perceptions of potential barriers for patients (80,81,166,184). African 
American/Black women have expressed frustration about not being informed about PrEP, 
and not trusting their providers as reliable sources of information about PrEP (92,93). 
Yet, in one study, African American/Black women were twice as likely as non-African 
American/Black women to consider taking PrEP, indicating that there is willingness to 
take PrEP among African American/Black women (187). A shared decision-making 
approach can help introduce the innovation (PrEP) to WOC, by centering WOC’s 
experiences and desires, and building trust between staff/provider and patient, therefore 
providing WOC with a more comprehensive range of HIV prevention options. Those 
who provide PrEP counseling (e.g., the PrEP coordinator, providers, nurses, case 
managers, counselors) should be trained in this approach.  
A patient decision support tool could facilitate a shared decision-making approach 
and offer a structured process. These tools are typically self-administered by patients and 
may involve brief educational modules, a risk assessment, and a path for choosing a 
preferred outcome. An evaluation of a tool used in family planning found that women 
who used the tool reported higher satisfaction and felt more informed than women who 
did not use the tool (188). A PrEP patient decision support tool for MSM is currently 
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being evaluated in Boston, MA, while similar tools are in development for young women 
(189–191). These tools can offer a more tailored approach to PrEP, while also allowing 
women to choose the information that is most relevant for them (e.g., available HIV 
prevention options for their specific risk factors).   
 
PrEP for young women under the age of 18 requires special confidentiality 
considerations. A recent study found that concerns about confidentiality were associated 
with a lower willingness to take PrEP among a sample of adolescents and young adults 
(71% Black, 59%, aged 18-25) in an ED setting (192). Participants from site B, which 
focused on providing PrEP to young women aged 13-24, reported hesitancy about 
bringing up PrEP with patients under the age of 18 as they were concerned about 
protecting minors’ confidentiality. Though the site had a confidentiality policy for minors 
in place, participants were unsure of how this policy extended to PrEP and desired more 
guidance. The CDC, ACOG, and the American Association of Family Physicians 
(AAFP) recommend the following components in confidentiality policies for minors: 1) 
explaining to parents that taking a sexual health history is routine and necessary practice; 
2) offering patients an exam room separate from their parents; 3) informing patients of 
the confidentiality policy; and 4) alerting patients to any restrictions on the policy (193–
Strategy #8: An institutional confidentiality policy for minors should ideally include: 
offering patients an exam room separate from their parents; informing patients of the 
confidentiality policy; and alerting patients to any restrictions on the policy. Construct 
addressed: context 
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195). Though these policies are likely challenging in an ED context, the institution of 
these policies is needed to provide care sensitive to young women’s needs. 
5.3 Recommendations for health policy 
This study’s findings reveal several recommendations for health policy. As the 
USPHS guidelines for PrEP eligibility for women with “substantial risk” are vague, 
clarity is needed. A 2019 study examining the utility of USPHS guidelines for identifying 
women as PrEP candidates found that the guidelines may miss a significant number of 
women at risk for HIV or who are motivated to take PrEP (64). This study concludes that 
the guidelines should inform users of the limitations of the eligibility criteria and promote 
routinizing PrEP into women’s health care (64). Further, guidelines should explain how 
to discuss PrEP with women who may not disclose or know their risk factors for HIV. 
USPHS should consult with providers from a range of specialties (e.g., family planning, 
infectious disease, primary care), as well as clinical support staff who counsel on PrEP to 
understand how the guidelines are used in practice, identify deficiencies, and refine the 
guidelines.  
On the state and federal level, the removal of prior authorization requirements for 
PrEP would relieve a significant provider barrier and improve access for patients. 
Funding that supports women’s access to preventive health care should be protected, 
including contraceptives, PrEP, and annual physicals. These efforts should include 
protecting Title X federal funding, which ensures women’s access to basic reproductive 
and preventive health care (196). For women who are unaware of PrEP, their annual 
preventive health visit may be one of few opportunities for them to learn about PrEP. 
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PrEP providers can be advocates for women by informing policymakers how Title X 
funding supports women’s health, such as sharing examples of how PrEP has positively 
affected their patients’ health and promoting women’s voices in sharing their own 
experiences with PrEP (e.g., invite women to speak with policymakers directly). 
As research indicates that adolescents are developmentally able to make their own 
health care decisions (197), institutions that serve adolescents should review their 
confidentiality policies to determine how they might affect conversations about PrEP 
with young people under the age of 18. To the extent allowed by local laws and 
regulations, health institutions should protect adolescents’ confidentiality related to 
sexual health care decisions. In addition to institutional policies, state laws should support 
adolescent autonomy in their health care decision-making. Per the recommendation of the 
Society of Adolescent Health and Medicine and the American Academy of Family 
Physicians, this should include laws such as withholding service information in insurance 
billing to protect the confidentiality of a young person who is a dependent on a 
parent/guardian’s insurance policy (194,195).   
5.4 Recommendations for future research 
 This study provides needed insight into the perspectives of staff and providers 
regarding PrEP implementation for WOC. As WOC’s preferences may differ from those 
of other groups (e.g., MSM), research focused specifically on their experiences and 
desires is necessary to tailor PrEP services to WOC. Some research is already underway: 
the University of Rochester Medical Center is conducting a study to understand reasons 
for low PrEP uptake among WOC (198). Also, understanding preferences among WOC 
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regarding how and from whom they receive PrEP information (e.g., from providers, 
trained lay persons, peer educators, or other sources, such as patient decision support 
tools) will help better serve this population. Knowing when and where WOC prefer to 
receive PrEP information is also needed, such as in clinic or out of clinic, during annual 
well women’s visits, or at every office visit. Research should also focus on YWOC’s 
preferences for PrEP, as their preferences may differ from adult WOC. Future research 
should evaluate using a shared decision-making approach for PrEP counseling with 
WOC. This evaluation should consider what materials and strategies are helpful for the 
staff and providers (e.g., EMR template), and the patient (e.g., patient decision support 
tools).  
Future studies should also investigate the role of the funding agency in similar 
initiatives (e.g., how funders can best facilitate implementation). For example, in this 
initiative, participants from each site identified monthly phone calls held by the funder as 
a helpful opportunity to discuss implementation efforts with other sites. Qualitative 
inquiry on similar initiatives that reflects on the funders’ role will provide insight on how 
funders can best support PrEP for WOC.  
5.5 Utility of the i-PARIHS framework 
The i-PARIHS framework proved helpful in investigating implementation and 
identified several gaps in facilitation. A strength of the i-PARIHS framework is that it 
recognizes facilitation as an active and ongoing process rather than a transactional 
delivery of information to staff. By extension, the facilitator (e.g., the PrEP coordinator) 
has multiple opportunities to assess and respond to implementation. I used these findings 
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to develop practice recommendations in order to guide future implementation; these 
recommendations should be viewed as a starting point for clinics as they implement 
PrEP.  
The application of the i-PARIHS framework uncovered specific contextual 
factors to be considered in implementation. Participants from each site described 
contextual factors that supported implementation (e.g., participants at site B reported that 
YWOC utilized the ED for sexual and reproductive health care, which supported 
reaching YWOC with PrEP information; participants from site A and C discussed that 
their relationships within the other initiative sites helped troubleshoot challenges and 
identify implementation strategies). However, as implementation progressed, contextual 
factors also presented barriers (e.g., the challenge of coordinating implementation across 
departments; limitations in current systems, such as the EMR). These factors need to be 
considered both in the planning stages prior to and throughout implementation. Though a 
context may seem appropriate for implementation, other factors may be barriers. Indeed, 
the ED was viewed as an ideal setting to reach YWOC; however, logistical and 
institutional factors (e.g., lack of time and space, concerns about confidentiality) created 
significant challenges. As PrEP is rolled out for women, leveraging contextual factors 
that enhance implementation but also examining which of these factors inhibit 
implementation can support reaching women. 
Another strength of the i-PARIHS framework is the recognition of the recipients 
(e.g., staff and providers) as a key element in implementation, whereas the framework’s 
previous iteration did not (147). The recipient construct refers to those who are involved 
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in the implementation, including their capacity, skills, values, and beliefs related to the 
innovation (147). Staff and providers are active participants in implementation, rather 
than solely performing discrete functions. Within the recipients construct, I was able to 
explore how participants’ attitudes and skills influence their acceptance and uptake of the 
innovation, PrEP. Recipients experienced significant barriers to implementation, 
including discomfort counseling on PrEP. Understanding how staff and providers 
received PrEP revealed opportunities for improved facilitation, such as targeted and 
ongoing training, to address their concerns.  
The framework provided a useful structure for examining participants’ 
perspectives on implementation barriers and facilitators. However, mapping the findings 
to the constructs was at times murky due to the interrelatedness of the constructs. For 
example, I categorized time limitations, a barrier cited by participants across sites, as a 
recipient-related barrier, as time is related to their capacity to implement the new 
innovation, PrEP, and to the value they place on prioritizing PrEP with patients. 
However, time limitations could also be considered a contextual factor (limited time as 
part of the clinic’s culture) as the context construct includes factors within the clinic 
setting that influence implementation (147). While utilizing the constructs in the 
interviews was useful for probing into participants’ perspectives of implementation, I 
found that the findings could not always easily be mapped to a single construct as some 
of the identified themes related to multiple constructs. As future research is conducted 
with this framework, it will be helpful for researchers to discuss the limitations of 
categorizing findings by constructs. Despite this challenge, relating the findings to the 
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construct of facilitation was ultimately useful in developing recommendations.  
5.6 Study limitations 
The methodology used was appropriate to address the research aims. However, 
this study does contain limitations. I discuss these limitations and attempts to address 
them below. 
Transferability of findings. Findings from the case studies presented here represent a 
range of perspectives (e.g., health promotion staff, clinical support staff, and providers) 
that provide useful insights into PrEP implementation for WOC at three different health 
care settings, filling a gap in the current literature. However, case studies and qualitative 
data are not generalizable as they aim to explore topics in-depth and within their specific 
contexts. Therefore, it may not be appropriate to apply all of the findings or the guidance 
developed here to settings other than the ones included in this study, such as specialty 
clinics. Though case studies and qualitative data may not offer statistical generalization, 
they provide in-depth understanding of implementing innovative interventions, such as 
PrEP (43). Recommendations provided here will support PrEP implementation for WOC, 
but need to be adapted to fit within the local context and population. 
Participant retention. I conducted baseline and follow-up interviews, approximately six 
months apart, in order to examine implementation longitudinally. Ideally, those who 
participated in baseline interviews would have also participated in the follow-up 
interviews to provide insight into how their views and experiences changed throughout 
the course of the program. I was flexible with participants by conducting interviews in-
person or over the phone, and conducting interviews outside of typical business hours. 
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However, due to staff turnover across sites and their limited availability, not everyone 
who participated in the baseline interviews also participated in the follow-up interviews.  
Limitations of administrative data. To fulfill aim 1.1, this study relied on routine 
administrative data. This study intended to utilize a broader range of indicators related to 
program outcomes and patient demographics. However, upon attempts to verify data for 
quality assurance, it became apparent that the administrative data were significantly 
limited. For example, sites did not report certain indicators such as the demographics of 
women screened for PrEP eligibility.   
Researcher bias. My own experiences, social identities, and knowledge may have 
introduced bias into the research. In order to reduce bias, I followed a formal process for 
data collection and analysis informed by a theoretical framework. I also attempted to 
practice reflexivity by recognizing how I brought my own experiences and ideas into the 
research process (145,199). I practiced reflexivity through: 1) presentation of this 
dissertation’s aims, research plans, and dissemination plan to participating sites and 
participants; 2) development of neutrally-worded interview guides; 3) site participation in 
data interpretation; 4) completion of field notes and analytic memos that provided space 
to reflect about the research process, such as noting any non-verbal cues or potential 
themes in development; and 5) involvement of another research team member (the RA) 
in qualitative data analysis.  
5.7 Conclusion 
 Previous research has explored WOC and providers’ perspectives of PrEP 
(19,84,111,91–94,99,102,103,107), yet none have studied PrEP implementation for WOC 
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in a real world setting. WOC face unique vulnerabilities to HIV infection and barriers to 
HIV prevention, and thus require tailored service delivery. While PrEP offers an 
additional method of HIV prevention for WOC, few programs offer PrEP to this 
vulnerable population. The initiative studied here was a novel attempt to fill this gap. 
While sites met their goals related to the number of staff and providers trained in PrEP, 
sites fell short in the number of WOC provided PrEP information or PrEP counseling, 
and only three of the targeted 387 WOC were prescribed PrEP.  
This study identified implementation barriers and facilitators related to the 
constructs of innovation, recipients, and context that are critical to consider in PrEP 
implementation for WOC. Though the sites seemed well-positioned to provide PrEP for 
WOC, support for PrEP did not overcome the cited barriers. These case studies 
demonstrate that PrEP integration into a clinic needs to be carefully considered. Staff 
need to be comprehensively trained in the components of PrEP (e.g., screening and 
counseling) and understand their roles in implementation. Successful implementation 
cannot occur without strong facilitation that assesses and reassesses the implementation 
process. Opportunities exist to address staff-identified barriers, including utilizing a PrEP 
coordinator to lead implementation, clarifying staff roles and responsibilities, providing 
ongoing feedback and targeted training to staff, and incorporating a shared decision-
making approach in PrEP counseling to ensure that WOC receive care sensitive to their 
needs and experiences. The HIV epidemic can only be fought by utilizing all available 
HIV prevention tools in combination with HIV treatment, delivered with consideration of 
the local context and population. Recommendations for practice identified here can be 
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used to support clinics as they provide PrEP to WOC.  
Table 10. Practice recommendations and related strategies for PrEP delivery to WOC 
Practice recommendation 1: Clarify staff roles and responsibilities 
1. Site leadership should specify a PrEP coordinator to facilitate implementation.  
2. Prior to implementation, the PrEP coordinator(s) should clearly specify staff roles, 
responsibilities, and opportunities to engage women. 
3. The PrEP coordinator(s) should identify opportunities to shift the responsibility of 
PrEP counseling from providers to lay staff. 
 
Practice recommendation 2: Engage staff through ongoing feedback and targeted 
training 
4. The PrEP coordinator(s) should incorporate targeted and ongoing booster training 
sessions and check-ins that include providing updated data on the program’s 
progress. 
5. The PrEP coordinator(s) should identify and showcase those staff who adopt PrEP 
as champions, as well as consult with these staff to improve PrEP implementation. 
 
Practice recommendation 3: Ensure care is focused on WOC’s needs and experiences 
6. PrEP should be integrated into routine, sexual, and reproductive health care visits 
for all women.  
7. Staff and providers should be trained to take a shared decision-making approach to 
PrEP counseling. 
8. Institutional confidentiality policy for minors should ideally include: offering 
patients an exam room separate from their parents; informing patients of the 
confidentiality policy; and alerting patients to any restrictions on the policy. 
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APPENDICES 
Appendix A. Supplemental tables 
 
Supplemental Table 1. US Department of Health and Human Services, ART initiation 
expert panel recommendations, updated January 28, 2017 (1) 
• ART is recommended for all HIV-infected individuals, regardless of CD4 
count, to reduce the morbidity and mortality associated with HIV infection. 
• ART is recommended for all HIV-infected individuals to prevent HIV 
transmission. 
• When initiating ART, patients are to be educated on benefits and considerations 
regarding ART, including adherence maintenance.  
• ART initiation may be deferred on a case-by-case basis because of clinical 
and/or psychosocial factors, but initiation should begin as soon as possible.  
 
 
Supplemental Table 2. Selected demographics of DC wards, 2011 (200,201) 
 Ward 1 
Ward 
2 
Ward 
3 
Ward 
4 
Ward 
5 
Ward 
6 
Ward 
7 
Ward 
8 
African 
American/Black, 
non-Hispanic/Latino 
35 15 5 62 49 444 95 94 
White, non-
Hispanic/Latino 38 65 77 18 11 44 2 3 
Median income $ 64,973 78,870 97,257 58,668 47,402 78,449 36,828 30,653 
Medicaid 
Enrollment % 10 13 1 14 14 11 18 20 
Supplemental Table 3. List of PrEP service locations in Washington, DC (34) 
Site Ward Type of facility 
Mary’s Center 1 FQHC 
Howard University Hospital Center for 
Infectious Disease Research and Management  
1 Hospital-based clinic 
Capital Medical Associates 2 Primary care 
Q Street Medical Associates 2 Primary care 
Medics USA 2 Primary care 
Dupont Circle Physicians Group 2 Primary care 
Whitman-Walker Health 2 LGBT community health 
center 
MetroHealth 2 Not-for-profit health clinic 
One Medical Group 2 Primary care 
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Supplemental Table 4. US Public Health Service 2017 summary of guidance criteria 
for PrEP use (46) 
 Men who have sex 
with men 
Heterosexual men 
and women 
Injection drug users 
Detecting 
substantial risk of 
acquiring HIV 
infection 
• HIV-positive 
sexual partner 
• Recent bacterial 
STI 
• High number of 
sex partners 
• History of 
inconsistent or 
no condom use 
• Commercial sex 
work 
• HIV-positive 
sexual partner 
• Recent bacterial 
STI 
• High number of 
sex partners 
• History of 
inconsistent or 
no condom use 
• Commercial sex 
work 
• In high-
prevalence area 
or network 
• HIV-positive 
injecting partner 
• Sharing injection 
equipment 
• Recent drug 
treatment (but 
currently 
injecting) 
 
Clinical eligibility • Documented negative HIV test result before prescribing PrEP 
• No signs/symptoms of acute HIV infection 
• Normal renal function 
• No contraindicated medications 
• Documented hepatitis B virus infection and vaccination status 
Prescription Daily, continuing, oral doses of TDF-FTC (Truvada), ≤90-day 
supply 
Follow-up services • At least every 3 months provide the following: HIV test, 
medication adherence counseling, behavioral risk reduction 
support, side effect assessment, and STI symptom assessment 
• At 3 months and every 6 months thereafter, assess renal 
function 
• Every 3-6 months, test for bacterial STIs 
• Oral/rectal STI 
testing 
• Assess 
pregnancy intent 
• Access to clean 
needles/syringes 
PrEP Clinic at Andromeda 4 Community health center 
(focus population: transgender 
persons) 
DC Health and Wellness Center 5 Municipal STI Clinic 
Providence Center for Infectious Disease 5 Hospital-based clinic 
Whitman-Walker Health – Max Robinson 
Center 
5 LGBT community health 
center 
United Medical Center 8 Hospital-based clinic 
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Supplemental Table 4. US Public Health Service 2017 summary of guidance criteria 
for PrEP use (46) 
 Men who have sex 
with men 
Heterosexual men 
and women 
Injection drug users 
• Pregnancy test 
every 3 months 
and drug 
treatment services 
 
Supplemental Table 5. US Public Health Service recommended indications for PrEP 
use by heterosexually active men and women (46) 
• Adult person 
• Without acute or established HIV infection  
• Any sex with opposite sex partners in past 6 months 
• Not in a monogamous partnership with a recently tested HIV-negative partner 
AND at least one of the following 
• Is a man who has sex with both women and men (behaviorally bisexual)  
• Infrequently uses condoms during sex with 1 or more partners of unknown HIV 
status who are known to be at substantial risk of HIV infection (person who injects 
drugs or bisexual male partner) 
• Is in an ongoing sexual relationship with an HIV-positive partner 
• A bacterial STI (syphilis, gonorrhea in women or men) diagnosed or reported in 
past 6 months 
 
Supplemental Table 6. US Public Health Service risk behavior assessment for 
heterosexual men and women (46) 
In the past 6 months: 
• Have you had sex with men, women, or both?  
o (if opposite sex or both sexes) How many men/women have you had sex with? 
• How many times did you have vaginal or anal sex when neither you nor your 
partner wore a condom? 
• How many of your sex partners were HIV-positive? 
o (if any positive) With these HIV-positive partners, how many times did you 
have vaginal or anal sex without a condom? 
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Supplemental Table 7. Completed and ongoing US PrEP demonstration projects as of 
May 2019 (202) 
Project name Location Focus population Status 
Los Angeles County 
(LAC) PATH PrEP 
Los Angeles, CA MSM and 
transgender women 
Completed 
The Demonstration 
Project 
San Francisco, CA; 
Washington, DC; Miami, 
FL  
MSM and 
transgender women 
Completed 
HPTN 073 Washington, DC; Los 
Angeles, CA; Chapel Hill, 
NC 
African 
American/Black 
MSM 
Completed 
Project PrEPare Baltimore, ML; Boston, 
MA; New York, NY; 
Chicago, IL; Washington, 
DC; Denver, CO; Detroit, 
MI; Houston, TX; Los 
Angeles, CA; Memphis, 
TN; Miami, FL; New 
Orleans; LA; Philadelphia, 
PA; Tampa, FL 
Young MSM Completed 
PrEP Adherence 
Enhancement Guided 
by iTAB and Drug 
Levels for Women 
(AEGIS) 
CA Female sex workers Ongoing 
East Bay 
Consortium/Connecting 
Resources for Urban 
Sexual Health 
(CRUSH) 
East Bay, CA Young MSM of 
color 
Ongoing 
Sustainable Health 
Center Implementation 
PrEP Pilot Study 
(SHIPP) 
Washington, DC; Chicago, 
IL; Philadelphia, PA; 
Jackson, MS 
MSM and 
heterosexual 
women 
Ongoing 
SPARK Project New York, NY MSM and 
transgender women 
Ongoing 
DISCOVER USA, Canada, Austria, 
Denmark, France, Germany, 
Italy, Ireland, Netherlands, 
Spain, UK, Scotland 
MSM and 
transgender Women 
 
Ongoing 
Linking Women to 
PrEP Care 
Rhode Island Women Ongoing 
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Supplemental Table 7. Completed and ongoing US PrEP demonstration projects as of 
May 2019 (202) 
Project name Location Focus population Status 
PrEP Implementation 
with US 
HIVSerodiscordant 
Couples: Couples PrEP 
Demo Project 
New York, New York Serodiscordant 
couples 
Ongoing 
The Stay Study: A 
Demonstration Project 
Advancing PrEP 
Delivery in the San 
Francisco Bay Area 
Transgender 
Community 
San Francisco, California Transgender 
individuals 
Ongoing 
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Appendix B. Supplemental figures 
 
Supplemental Figure 1. New HIV diagnoses in the US for the most-affected 
subpopulations (203) 
 
 
 
Supplemental Figure 2. New TDF-FTC for PrEP starts by race/ethnicity 
and age, 2012-2015 (25) 
 
Data were collected from national, electronic, patient-level data from US retail 
pharmacies. 
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Supplemental Figure 3. Number of newly diagnosed HIV cases and living HIV cases 
by year District of Columbia, 2012-2016 (30) 
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Appendix C. Interview guides  
 
INTERVIEW GUIDE FOR MIDLINE 
 
Brief introduction 
• Thank you for participating 
• Project description 
• Oral reading of the research information sheet 
• Participants will be given my business card with contact information 
 
Interview guide 
 
1. Background 
A. I would like to first learn about you and your role in the initiative. What is your 
role in the PrEP for Women Initiative? 
a. How do you think this initiative will affect your patients or clients? 
b. Do you think this is an important initiative? Why? 
B. Now I’d like to learn about the launch of the initiative.  
a. Who was involved in the launch of the initiative (who is leading it)? 
i. Are these medical doctors, nurse practitioners, nurses, other staff?  
b. Who created the training?  
i.  For those who created the training, what is their background? 
Medical doctors, nurses, public health practitioners (MPH), etc?  
c. Who conducted the training? 
i. For those who led the training, what is their background? Medical 
doctors, nurses, public health practitioners (MPH), etc? 
d. Who received the training?  
i. For those who received the training, what is their background? 
Medical doctors, nurses, public health practitioners (MPH), etc? 
e. What training did you in particular receive for the initiative?  
f. What was the training process? 
i. Who led your training? 
ii. What did you learn that was new? 
iii. What would you like to learn more about? 
C. Do you engage patients in PrEP counseling or initiation? 
a. If yes, please describe in detail how you approach potential patients about 
PrEP counseling and/or initiation (if medical provider). 
b. How do you decide which patients or clients to speak with about PrEP? 
i. What steps do you go through to determine if a woman is eligible? 
1. How do you assess PrEP eligibility?  
2. Do you use a universal screener?  
c. How do you discuss PrEP with the patients? 
i. What tools do you use when engaging in PrEP counseling or 
initiation?  
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d. What have been patients’ reactions to PrEP counseling and/or initiation? 
i. What questions have patients asked? 
e. How do you respond when a patient is not interested, or refuses PrEP 
counseling or initiation? 
i. Why do you think your patients or clients are not interested in 
PrEP counseling or initiation? 
D. It is about halfway through the program year. What parts of the initiative have 
been implemented so far?  
a. What parts of the initiative are you directly responsible for implementing? 
E. What has not been implemented that you would have hoped to at this point? 
  
2) I-PARIHS Construct: Innovation 
A. What parts of this initiative are working and why? 
B. What parts are not working and why? 
C. What has helped you to implement this initiative? 
a. This could be things like a clinic flow process; standardized screening 
tools; EMR templates?  
i. How were these processes/tools developed? 
ii. Who developed these processes/tools?  
D. What are the main challenges to implementing this initiative? 
a. These could be things like clinic flow challenges; billing/reimbursement 
challenges; challenges to the patient (lost to follow up); challenges with 
lab/blood work? 
E. For each challenge, what suggestions do you have to overcome these challenges 
to implementation? 
F. How would you describe success of this initiative?  
a. How will you know when this initiative has been successful? 
 
3) I-PARIHS Construct: Recipients 
A. How much of a priority is this initiative to you?  
a. How much of a priority is this initiative to your team?  
b. How much of a priority is this initiative to leadership? 
B. What are the necessary skills and training needed for your position to carry out 
the proposed initiative? 
a. Do you feel that you have received enough training to have these skills?  
b. What did you learn that you did not realize was needed for this initiative 
(in other words, what did you not know that you did not know)? 
C. Does the staff/team have the necessary skills and training to carry out the 
proposed initiative? 
D. What resources, such as support staff or counseling tools, are available to support 
implementation? 
E. What motivates the team to implement this initiative?  
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4) I-PARIHS Construct: Context 
A. How well does the PrEP for Women Initiative fit within your clinic?  
B. How are staff involved in decisions that affect them? 
C. Who are the formal leaders of this initiative?  
a. How have the formal leaders assisted in the implementation? 
D. Who are the informal leads of this initiative?  
a. How have the informal leaders assisted in implementation?  
E. What mechanisms are in place to support learning and evaluation related to the 
initiative’s implementation, such as feedback loops or meetings? 
F. What systems challenges are there, if any? 
a. These could be things like patient administration, workflow, management, 
quality assurance, reimbursement procedures, insurance challenges. 
G. What barriers (real or perceived) has your patient population faced with PrEP 
initiation? 
a. How do you address these barriers with your patients? 
H. How does the wider health system, such as local or national priorities and 
policies, influence your implementation of initiative? 
 
5) Moving forward 
a) What are 1-2 key things you have learned from implementing this initiative so 
far? 
b) Any further suggestions or recommendations on how this implementation process 
might be improved? 
c) Is there anything you want to discuss that has not already been discussed? 
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INTERVIEW GUIDE FOR ENDLINE 
 
Brief introduction 
• Thank you for participating 
• Project description 
• Oral reading of the research information sheet 
• Participants will be given my business card with contact information 
 
Interview guide 
 
1. Background 
A. I would like to first learn about you and your role in the initiative. What is your 
role in the PrEP for Women Initiative? 
a. How do you think this initiative will affect your patients or clients? 
b. Why do you think that (above affects)? 
B. How are you involved in the initiative?  
a. What parts of this initiative are you directly responsible for?  
b. How were you trained for this initiative? 
C. How do you engage women in this initiative?  
a. How do you approach potential women about PrEP and/or initiation? 
b. How do you decide which patients or clients to speak with about PrEP? 
c. How do you discuss PrEP with the patients? 
i. How do you use tools or materials to engage women about PrEP?  
d. How have patients reacted to PrEP counseling and/or initiation? 
i. Why do you think they react this way?  
ii. What questions have patients asked? 
e. How do you respond when a patient is not interested, or refuses PrEP 
counseling or initiation? 
i. Why do you think your patients or clients are not interested in 
PrEP counseling or initiation? 
D. The initiative has now been underway for 12 months. 
a. How has implementation been what you expected? Why? 
b. How has implementation been not what you expected? Why?   
i. What has not been implemented that you would have hoped to at 
this point?  
E. What has not been implemented that you would have hoped to at this point?  
 
2) I-PARIHS Construct: Innovation 
A. How has this initiative been working for you and why? 
B. How has this initiative not been working for you and why? 
C. What has helped you to implement this initiative? 
b. This could be things like a clinic flow process; standardized screening 
tools; EMR templates?  
i. How were these processes/tools developed? 
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ii. Who developed these processes/tools? 
c. How have these facilitators affected implementation? 
D.  What are the main challenges to implementing this initiative? 
d. These could be things like clinic flow challenges; billing/reimbursement 
challenges; challenges to the patient (lost to follow up); challenges with 
lab/blood work? 
e. How have these challenges affected implementation?  
f. How might these challenges or barriers be overcome?  
F. How would you describe success of this initiative?  
g. How will you know when this initiative has been successful? 
 
3) I-PARIHS Construct: Recipients 
A. How much of a priority is this initiative to you?  
a. How much of a priority is this initiative to your team?  
b. How much of a priority is this initiative to leadership? 
B. What are the necessary skills and training needed for your position to carry out 
the proposed initiative? 
a.  What would you like to learn more about to help you implement the 
initiative?   
b. What did you learn that you did not realize was needed for this initiative 
(in other words, what did you not know that you did not know)? 
C. Does the staff/team have the necessary skills and training to carry out the 
proposed initiative? 
D. How are resources, such as support staff or counseling tools, available to support 
implementation? 
E. Why is the team motivated to implement this initiative?  
 
4) I-PARIHS Construct: Context 
A. How well does the PrEP for Women Initiative fit within your clinic?  
B. How are staff involved in decisions that affect them? 
C. Who are the formal leaders of this initiative?  
a. How have the formal leaders assisted in the implementation? 
D. Who are the informal leads of this initiative?  
a. How have the informal leaders assisted in implementation?  
E. What mechanisms are in place to support learning and evaluation related to the 
initiative’s implementation, such as feedback loops or meetings? 
F. What systems challenges are there, if any? 
a. These could be things like patient administration, workflow, management, 
quality assurance, reimbursement procedures, insurance challenges. 
b. How have these challenges affected implementation?  
G. What barriers (real or perceived) has your patient population faced with PrEP 
initiation? 
a. Why are these barriers?  
b. How do you address these barriers with your patients? 
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H. How does the wider health system, such as local or national priorities and 
policies, influence your implementation of initiative? 
 
5) Moving forward 
A. What are 1-2 key things you have learned from implementing this initiative so 
far? 
B. Any further suggestions or recommendations on how this implementation process 
might be improved? 
C. Is there anything you want to discuss that has not already been discussed? 
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Appendix D. Washington AIDS Partnership blank quarterly progress report 
 
Washington AIDS Partnership 
 
PrEP for Women Initiative Quarterly Report 
 
Activities Completed: Please report on completed and in-progress activities for this grant for 
this quarter, including specific activities outlined in your project plan, if applicable. 
 
PrEP Education Indicators Reporting: Please report on numbers reached year to date for 
each of the following indicators.  
• YTD total number of clients served by the project  
• Total number of Females   
• Total number of Males  
• Total number of self-identified Transgender individuals  
• Total number of self-identified gender non-conforming individuals (excluding 
Transgender individuals)  
• YTD number of patients screened for STIs 
• YTD number of patients screened for HIV  
• YTD number of patients educated about PrEP  
 
PrEP Internal Integration Indicators Reporting:  Please report on numbers reached year to 
date for each of the following indicators. For reference, “internal” means within your 
organization. 
• YTD number of internal health providers educated about PrEP  
• YTD number of PrEP education sessions held for internal health providers  
• Number of internal health providers who report readiness to prescribe PrEP (post 
education session)  
• Number of internal health providers who are now prescribing PrEP for women as 
a result of this project  
• Please include any additional survey results that highlight the impact of this work.  
• YTD number of patients who received initial screening for PrEP  
• Number of patients screened for PrEP who were eligible for PrEP  
• Number of those eligible for PrEP who were referred to an internal or external 
provider  
• Number of those eligible for PrEP who were linked to an internal or external 
provider 
• Number of those eligible for PrEP who subsequently were prescribed PrEP  
• Number of those eligible for PrEP who subsequently were initiated on PrEP 
• Number of those initiated on PrEP who maintained adherence 
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PrEP External Capacity Building Indicators Reporting: Please report on numbers reached 
year to date for each of the following indicators. For reference, “external” means outside 
your organization. 
• YTD number of external health providers educated about PrEP, including number 
that received CME credit, if applicable  
• YTD number of PrEP education sessions held for external health providers 
(please detail the type of education provided, e.g. a course with CME credit, a 
webinar, a training at a local college, etc.)  
• Number of external health providers who report readiness to prescribe PrEP (post 
education session) 
• Please include any additional survey results that highlight the impact of this work  
 
Data Explanation:  
 
Barriers: Discuss any ongoing or anticipated barriers that may impact your activities and 
program goals.  
 
Successes: Provide a patient success story and detail a success that highlights your 
project’s impact.  
 
Challenges: What challenges has the project experienced to date? 
 
 
Supplemental Table 8. PrEP for Women Initiative: Patient/client demographic table, 
provided by the Washington AIDS Partnership 
Total Black/African 
American 
Asian/Pacific 
Islander 
Hispanic/ 
Latino 
White/ 
Caucasian 
Native 
American/ 
Alaskan 
Native 
Other/Mixed 
Total       
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Appendix E. Case studies’ supplemental tables 
 
Supplemental Table 9. Site A PrEP for Women Initiative overview of main 
components 
Component Description 
1. Internal staff training 
in PrEP 
• The clinical lead and education lead developed a PrEP 
101 training, which was delivered to all health 
education and clinical support staff and providers 
• Clinical support staff also received PrEP protocol 
training and training in taking a patient’s sexual health 
history 
2. Provide PrEP 
information to WOC  
• Health education team provided direct outreach to 
WOC at community-based events or clinic-sponsored 
events (e.g. school-based health curriculum) 
• Health education team implemented the marketing 
campaign with PrEP-branded materials (e.g. printed 
informational pamphlets), social media campaign, and 
search engine marketing  
• Health education team provided indirect outreach by 
training staff from health organizations that serve WOC 
3. Educate WOC about 
PrEP within the clinic 
• Medical assistants and providers conducted one-on-one 
counseling sessions with WOC 
4. Prescribe PrEP to 
WOC 
• WOC interested in PrEP could call the clinic’s hotline 
or scheduling line to set a PrEP-specific appointment   
 
Supplemental Table 10. Site A PrEP for Women Initiative timeline 
 Expected activities Completed activities 
Quarter 
1 
• Hire PrEP Education Manager 
• Develop internal PrEP training for 
staff 
• Develop PrEP marketing materials 
• Train all health education and 
clinical support staff in PrEP 
• Hired PrEP Education 
Manager 
• Developed internal PrEP 
training for staff 
• Began (but did not complete) 
training for health education 
and clinical support staff in 
PrEP 
Quarter 
2 
• Begin PrEP counseling and 
prescribing in clinic  
• Begin outreach and education 
activities  
• Completed training for health 
education and clinical support 
staff in PrEP 
• Completed development of 
PrEP marketing materials 
• Began outreach and education 
activities 
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Supplemental Table 10. Site A PrEP for Women Initiative timeline 
Quarter 
3 
• Continue outreach, education, and 
prescribing activities 
• PrEP Education Manager 
hired in Quarter 1 left, new 
PrEP Education Manager 
hired and trained  
• Completed additional training 
for providers and clinical 
support staff 
• Continued outreach and 
education activities 
• Began PrEP prescribing 
activities (i.e. opened up 
dedicated PrEP appointment 
times) 
Quarter 
4 
• Continue outreach, education, and 
prescribing activities 
• Continued outreach, 
education, and prescribing 
activities 
 
Supplemental Table 11. Site B PrEP for Women Initiative overview of main 
components 
1. Internal staff training in 
PrEP 
• The Project Director and PrEP Coordinator 
developed and implemented quarterly staff training 
focused on young women’s sexual health with an 
emphasis on HIV prevention and PrEP.  
2. Provide PrEP 
information to YWOC 
• All young women who participate in HIV/STI point 
of care testing program received a youth- and 
female-friendly PrEP educational pamphlet. 
• PrEP Coordinator provided PrEP counseling to 
young women who screened positive for a STI in 
the ED  
• For young women <18 years of age accompanied 
by guardian, PrEP Coordinator provided guardian a 
PrEP educational pamphlet with frequently asked 
questions about the use of PrEP among young 
women 
3. Prescribe PrEP to 
YWOC 
• PrEP offered to young women who screened 
positive for a STI 
4. Training external PCPs 
in PrEP to build capacity 
• PrEP Coordinator identified PCP of any young 
women who screened positive for a STI in the ED 
• PrEP Coordinator contacted PCPs and invited them 
to attend quarterly training session on PrEP for 
young women 
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Supplemental Table 12. Site B PrEP for Women Initiative timeline 
 Expected activities Completed activities 
Quarter 
1 
• Hire PrEP Coordinator 
• Develop PrEP educational materials 
for young women, and training 
materials for internal staff and 
external PCPs 
• Begin training internal staff in PrEP 
• Begin identification of external PCPs 
• Began development of PrEP 
educational materials for 
young women, and training 
materials for internal staff and 
external PCPs 
• Began identification of 
external PCPs 
Quarter 
2 
• Begin PrEP education, counseling, 
prescribing, and linkage to care 
activities for YWOC 
• Continue training internal staff in 
PrEP 
• Begin training external PCPs in PrEP 
• Completed development of 
PrEP educational materials for 
young women, and training 
materials for internal staff and 
external PCPs 
• Began PrEP education, 
counseling, and prescribing 
activities for YWOC  
• Began training internal staff in 
PrEP  
• Continued identification of 
external PCPs, extending 
invitation to receive PrEP 
training 
Quarter 
3 
• Continue PrEP education, 
counseling, prescribing, and linkage 
to care activities for YWOC 
• Continue training internal staff in 
PrEP 
• Continue training external PCPs in 
PrEP 
• Hired PrEP Coordinator 
• Continued PrEP education, 
counseling, and prescribing 
activities for YWOC  
• Continued training internal 
staff in PrEP 
• Continued identification of 
external PCPs, extending 
invitation to receive PrEP 
training 
Quarter 
4 
• Continue PrEP education, 
counseling, prescribing, and linkage 
to care activities for YWOC 
• Continue training internal staff in 
PrEP 
• Continue training external PCPs in 
PrEP 
• Continued PrEP education and 
prescribing activities for 
YWOC  
• Continued training internal 
staff in PrEP 
• Continued identification of 
external PCPs, extending 
invitation to receive PrEP 
training 
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Supplemental Table 13. Site C PrEP for Women Initiative overview of main 
components 
1. Internal staff training in PrEP • The PrEP Coordinator developed and 
implemented a 2-sessions training for health 
education and clinical support staff.   
2. Provide PrEP information to 
WOC 
• The PrEP Coordinator, with support from 
health education staff, provided direct 
outreach to WOC at community-based events 
or events sponsored by Mary’s Center. 
• All WOC patients received PrEP screening 
and information.  
3. Prescribe PrEP to WOC • Providers screened all WOC and referred 
WOC to the PrEP Coordinator to establish 
PrEP treatment plan. The PrEP Coordinator 
counseled WOC on PrEP, and if women were 
interested, the PrEP Coordinator proceeded 
with provider’s PrEP treatment plan.  
 
Supplemental Table 14. Site C PrEP for Women Initiative timeline 
 Expected activities Completed activities 
Quarter 
1 
• Hire PrEP Coordinator 
• Train all internal staff 
• Began training of internal staff 
• Begin PrEP information, counseling, 
and prescribing activities 
 
Quarter 
2 
• Begin PrEP information, 
counseling, and prescribing 
activities 
• Continue internal staff 
training 
• Hired PrEP Coordinator 
• PrEP Coordinator developed new 2-
session training for internal staff. First 
session conducted in quarter 2 
• Began PrEP information and 
counseling activities 
Quarter 
3 
• Continue PrEP information, 
counseling, and prescribing 
activities for WOC 
• Continue internal staff 
training 
• Continued internal staff training 
• Continued PrEP information and 
counseling activities 
• Began PrEP prescribing activities 
Quarter 
4 
• Continue PrEP information, 
counseling, and prescribing 
activities for WOC 
• Continue internal staff 
training 
• Continued internal staff training 
• Continued PrEP information and 
counseling activities 
• Continued PrEP prescribing activities 
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Appendix F. Public health product #1: Patient education tool 
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Appendix G. Public health product #2: PrEP implementation practice recommendations 
reference guide for health clinic staff and providers serving WOC 
 
Three Recommendations for Successful Implementation of PrEP for Women of Color:  
A Reference Guide 
 
Overview 
Researchers examining the perspectives of health clinic staff and providers about PrEP 
implementation for women of color (WOC) identified three major practice 
recommendations that aim to improve implementation for this vulnerable, yet 
underserved population. Specific strategies are provided to accomplish these 
recommendations.  
 
Practice recommendation 1: Clarify staff roles and responsibilities. 
 
Strategy #1: Site leadership should specify a PrEP coordinator(s) to facilitate 
implementation. For PrEP programs that are cross-departmental, a coordinator from each 
department is recommended. Dedicated staff would be responsible for leading 
implementation in order to harmonize efforts and balance priorities across departments 
(e.g., clinical and health education).  
 
Strategy #2: Prior to beginning implementation, the PrEP coordinator(s) should clearly 
specify staff roles, responsibilities, and opportunities to engage women in order to 
establish a standard procedure for how PrEP information gets to women (including which 
staff are responsible for engaging women at different care points, such as screening, 
counseling, monitoring) and to ensure that staff understand their role(s) in 
implementation. 
 
Strategy #3: The PrEP coordinator(s) should identify opportunities to shift the 
responsibility of PrEP counseling from providers to lay staff (e.g., case managers, 
counselors) in order to decrease the time burden on providers and allow for more time 
focused on PrEP counseling by staff who are not as time-limited as providers.  
 
Practice recommendation 2: Engage staff through ongoing feedback and 
targeted training 
 
Strategy #4: The PrEP coordinator(s) should incorporate targeted and ongoing booster 
training sessions that include providing updated data on the program’s progress in order 
to increase staff and provider comfort in their roles and facilitate staff investment in 
implementation. 
 
Strategy #5: The PrEP coordinator(s) should identify and showcase those staff who adopt 
PrEP as champions, as well as consult with these staff to improve PrEP implementation, 
in order to highlight positive role models for other staff, encourage investment in PrEP, 
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and create a liaison between the coordinator(s) and those directly involved in 
implementation. 
 
Practice recommendation 3: Ensure care is focused on WOC’s needs and 
experiences 
 
Strategy #6: PrEP should be integrated into routine, sexual, and reproductive health care 
visits for all women to ensure providers are not missing women who are eligible or 
interested in PrEP, and decrease the time and cost burden on patients.  
 
Strategy #7: Staff and providers should be trained to take a shared decision-making 
approach to PrEP counseling in order to center WOC’s experiences and needs, allow for 
the exploration of barriers specific to WOC’s experiences, potentially uncover risks 
factors that would not be seen through a risk assessment checklist, and clarify / correct 
staff perceptions of potential barriers for WOC. 
 
Strategy #8: An institutional confidentiality policy for minors should ideally 
include: offering patients an exam room separate from their parents; informing 
patients of the confidentiality policy; and alerting patients to any restrictions on 
the policy, in order to provide young WOC with the opportunity to speak openly 
with staff and providers about their sexual health needs.   
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Appendix H. Abstract for draft manuscript 
 
 
Target journal: AIDS PATIENT CARE AND STDS 
 
Title: Implementation of HIV Pre-Exposure Prophylaxis for Women of Color: 
Perspectives from Health Clinic Staff and Providers 
 
Authors: Allison L. Kimmel, DrPH, MPH,1,* Lisa Messersmith, PhD, MPH,2 Angela R. 
Bazzi, PhD, MPH,1 Meg M. Sullivan, MD,3 Jacqueline Boudreau, MPH,1 and Mari-Lynn 
Drainoni, PhD4-7 
 
Women of color (WOC) account for 83% of new HIV infections among women in the 
US. While pre-exposure prophylaxis (PrEP) is a safe, effective method to prevent HIV 
acquisition, WOC are much less likely to be prescribed PrEP than other high-risk 
populations, leaving a major gap in HIV prevention options for WOC. Guided by the 
implementation science framework, integrated Promoting Action on Research 
Implementation in Health Services (i-PARIHS), we conducted a qualitative study of a 
PrEP initiative for WOC at three clinics in a major US city with high HIV incidence. 
Implementation was challenging: by the end of the first year only three out of the targeted 
387 WOC had been prescribed PrEP. Through semi-structured interviews with 24 clinic 
staff and providers, we identified several barriers to implementation at the clinic level, 
including staff time limitations, concerns about confidentiality, and discomfort with PrEP 
counseling. Facilitators included staff and leadership support of PrEP provision, the 
alignment of PrEP with the clinics’ missions, and having a centralized PrEP coordinator. 
Opportunities to improve PrEP for WOC include clarifying staff roles and 
responsibilities, providing ongoing feedback and targeted training to staff, and 
incorporating a shared decision-making approach in PrEP counseling. To provide WOC 
the full range of HIV prevention options, successful implementation will require a 
facilitation process that addresses the barriers and supports the facilitators to PrEP 
implementation.  
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